P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
9.808e-09 | -18.44 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 16 | 19454 | 50 |
MAML2,ATP1A2,SLC1A3,APOE,SPARCL1,LSAMP,AHCYL2,PTPRZ1,GPM6A,NHSL1,CLU,CPE,MSI2,TRPS1,QKI,SLC4A4 |
5.023e-08 | -16.81 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 44 | 16828 | 49 |
COL5A3,PON2,SPARCL1,SOX5,FBXL7,MSI2,DTNA,LSAMP,CLU,SLC4A4,AHCYL2,PITPNC1,NHSL1,CDH20,NTM,ATP13A4,FGFR3,HIF3A,TRPS1,HEPACAM,BMPR1B,NKAIN3,PTPRZ1,NPAS3,SLC1A2,QKI,HPSE2,TNIK,RYR3,RORA,NFIA,ZBTB20,GPC5,GPM6A,CPE,APOE,PARD3B,PREX2,SLC1A3,MAML2,ZNRF3,PCDH9,NRXN1,GLIS3 |
9.898e-08 | -16.13 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 3 | 10285 | 31 |
SLC1A3,SLC1A2,GLUL |
9.898e-08 | -16.13 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 3 | 10285 | 31 |
SLC1A2,GLUL,SLC1A3 |
1.813e-07 | -15.52 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 13 | 16828 | 49 |
GPC5,FBXL7,RYR3,HPSE2,MAML2,SOX5,PCDH9,PREX2,SLC1A2,NKAIN3,ATP1A2,LSAMP,COL5A3 |
2.059e-07 | -15.40 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 28 | 16828 | 49 |
SLC1A3,PREX2,LSAMP,CPE,PAMR1,SLC4A4,HIF3A,NRXN1,GLIS3,MAML2,NTM,PCDH9,ATP13A4,NKAIN3,PTPRZ1,SLC1A2,BMPR1B,COL5A3,FBXL7,NFIA,GPC5,ZBTB20,GPM6A,HPSE2,RYR3,TNIK,SOX5,RORA |
2.059e-07 | -15.40 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 28 | 16828 | 49 |
PREX2,SLC1A3,SLC4A4,CPE,PAMR1,LSAMP,GLIS3,NRXN1,HIF3A,PCDH9,ATP13A4,MAML2,NTM,SLC1A2,PTPRZ1,NKAIN3,COL5A3,BMPR1B,GPM6A,GPC5,ZBTB20,NFIA,FBXL7,RORA,RYR3,HPSE2,TNIK,SOX5 |
2.486e-07 | -15.21 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 25 | 16828 | 49 |
AHCYL2,LSAMP,CPE,SLC1A3,PREX2,CDH20,MAML2,PCDH9,FGFR3,ZNRF3,ATP13A4,PTPRZ1,SLC1A2,NPAS3,NKAIN3,RYR3,HPSE2,TNIK,SOX5,RORA,QKI,GPC5,ZBTB20,GPM6A,FBXL7 |
2.687e-07 | -15.13 | cell periphery | cellular component | GO:0071944 | 6020 | 33 | 19108 | 49 |
PREX2,CDH20,ZNRF3,NRXN1,DTNA,GPM6A,GPC5,CTNNA2,SLC4A4,NKAIN3,APOE,PCDH9,TNIK,CPE,HIF3A,SPARCL1,FGFR3,RYR3,LSAMP,PARD3B,NTM,PTPRZ1,SLC1A3,ATP1A2,CST3,GLUL,BMPR1B,PON2,COL5A3,SLC1A2,CLU,HPSE2,ATP13A4 |
3.120e-07 | -14.98 | nervous system development | biological process | GO:0007399 | 2185 | 20 | 18204 | 49 |
SOX5,SLC1A3,NRXN1,LSAMP,APOE,NFIA,CTNNA2,ATP1A2,NTM,TNIK,GPM6A,MSI2,PCDH9,PREX2,RORA,QKI,SLC1A2,PTPRZ1,BMPR1B,CLU |
3.509e-07 | -14.86 | multicellular organism development | biological process | GO:0007275 | 3957 | 27 | 18204 | 49 |
SLC1A3,HIF3A,ATP1A2,CTNNA2,LSAMP,NRXN1,BMPR1B,PTPRZ1,QKI,PCDH9,PREX2,CPE,GPM6A,TRPS1,ZNRF3,CDH20,SOX5,APOE,NFIA,FGFR3,RORA,SLC1A2,MSI2,NTM,TNIK,CLU,GLUL |
5.795e-07 | -14.36 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 22 | 16828 | 49 |
FBXL7,GPC5,ZBTB20,GPM6A,QKI,TNIK,RYR3,HPSE2,SOX5,MAML2,PCDH9,RORA,ATP13A4,ZNRF3,NKAIN3,PTPRZ1,PREX2,SLC1A3,CDH20,LSAMP,CPE,AHCYL2 |
6.811e-07 | -14.20 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
SLC1A2,NPAS3,PREX2,NKAIN3,ATP1A2,COL5A3,BMPR1B,LSAMP,NFIA,FBXL7,FGFR3,TNIK,HPSE2,RYR3,SOX5 |
6.811e-07 | -14.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
FBXL7,NFIA,SOX5,TNIK,HPSE2,RYR3,FGFR3,NKAIN3,PREX2,NPAS3,SLC1A2,LSAMP,BMPR1B,COL5A3,ATP1A2 |
6.920e-07 | -14.18 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 49 |
PCDH9,CPE,PREX2,GPM6A,TRPS1,BMPR1B,PTPRZ1,QKI,NRXN1,HIF3A,ATP1A2,CTNNA2,LSAMP,SLC1A3,GLUL,CLU,MSI2,NTM,TNIK,RORA,SLC1A2,FGFR3,APOE,NFIA,SOX5 |
9.787e-07 | -13.84 | cell junction | cellular component | GO:0030054 | 2224 | 19 | 19108 | 49 |
ATP1A2,HEPACAM,TNIK,PCDH9,APOE,FGFR3,SPARCL1,CLU,SLC1A2,QKI,PARD3B,PTPRZ1,CDH20,NFIA,SLC1A3,NRXN1,CTNNA2,GPM6A,DTNA |
1.275e-06 | -13.57 | neurogenesis | biological process | GO:0022008 | 1334 | 15 | 18204 | 49 |
SOX5,SLC1A3,NFIA,APOE,CTNNA2,NRXN1,PTPRZ1,QKI,RORA,BMPR1B,TNIK,GPM6A,NTM,PREX2,CLU |
1.606e-06 | -13.34 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 49 |
NRXN1,CTNNA2,NFIA,SLC1A3,CDH20,CLU,PREX2,TNIK,GPM6A,BMPR1B,PTPRZ1 |
2.063e-06 | -13.09 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 19 | 18204 | 49 |
FGFR3,NRXN1,HIF3A,CTNNA2,APOE,NFIA,SLC1A3,CDH20,SOX5,GLUL,CLU,PREX2,CPE,TNIK,GPM6A,BMPR1B,RORA,PTPRZ1,QKI |
2.650e-06 | -12.84 | plasma membrane | cellular component | GO:0005886 | 5538 | 30 | 19108 | 49 |
SLC1A3,PARD3B,NTM,PTPRZ1,GLUL,BMPR1B,PON2,SLC1A2,HPSE2,ATP13A4,ATP1A2,CST3,NRXN1,GPM6A,DTNA,GPC5,CTNNA2,PREX2,CDH20,ZNRF3,FGFR3,RYR3,LSAMP,SLC4A4,NKAIN3,APOE,PCDH9,TNIK,CPE,HIF3A |
3.226e-06 | -12.64 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 19 | 16828 | 49 |
GPM6A,GPC5,FBXL7,PCDH9,ATP13A4,RYR3,HPSE2,SOX5,MAML2,SLC1A2,NHSL1,NPAS3,SLC1A3,PREX2,NKAIN3,AHCYL2,CPE,BMPR1B,LSAMP |
3.226e-06 | -12.64 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 19 | 16828 | 49 |
AHCYL2,CPE,BMPR1B,LSAMP,SLC1A2,NHSL1,NPAS3,PREX2,SLC1A3,NKAIN3,PCDH9,ATP13A4,RYR3,HPSE2,SOX5,MAML2,GPM6A,GPC5,FBXL7 |
4.244e-06 | -12.37 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 18 | 16828 | 49 |
MAML2,SOX5,TNIK,HPSE2,RYR3,RORA,ZNRF3,FGFR3,PCDH9,NRXN1,ZBTB20,GPM6A,BMPR1B,COL5A3,PARD3B,AHCYL2,SLC4A4,NPAS3 |
4.307e-06 | -12.36 | larynx | COSMIC cancer mutations | larynx | 1948 | 18 | 16828 | 49 |
PCDH9,FGFR3,ZNRF3,RORA,TNIK,RYR3,HPSE2,SOX5,MAML2,GPM6A,ZBTB20,NRXN1,COL5A3,BMPR1B,AHCYL2,SLC4A4,PARD3B,NPAS3 |
7.570e-06 | -11.79 | anatomical structure development | biological process | GO:0048856 | 5207 | 29 | 18204 | 49 |
FGFR3,NFIA,APOE,CDH20,SOX5,GLUL,CLU,SPARCL1,MSI2,TNIK,NTM,SLC1A2,RORA,NRXN1,CTNNA2,ATP1A2,HIF3A,LSAMP,SLC1A3,COL5A3,CPE,PREX2,PCDH9,TRPS1,GPM6A,ZNRF3,BMPR1B,PTPRZ1,QKI |
7.967e-06 | -11.74 | generation of neurons | biological process | GO:0048699 | 1158 | 13 | 18204 | 49 |
NRXN1,NFIA,APOE,CTNNA2,SOX5,GPM6A,TNIK,NTM,PREX2,SLC1A3,PTPRZ1,RORA,BMPR1B |
1.002e-05 | -11.51 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 11 | 16828 | 49 |
MAML2,PARD3B,RYR3,HPSE2,PCDH9,CPE,QKI,PTPRZ1,NRXN1,GPC5,NPAS3 |
1.310e-05 | -11.24 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 49 |
TRPS1,HEPACAM,GLIS3,NRXN1,ATP13A4,FGFR3,PCDH9,MAML2,NTM,PITPNC1,NHSL1,PREX2,SLC1A3,PAMR1,CPE,LSAMP,SLC4A4,AHCYL2,PARD3B,NFIA,FBXL7,GPM6A,ZBTB20,GPC5,QKI,RORA,SOX5,TNIK,HPSE2,RYR3,NKAIN3,NPAS3,PON2,SLC1A2,PTPRZ1,COL5A3 |
1.584e-05 | -11.05 | developmental process | biological process | GO:0032502 | 5716 | 30 | 18204 | 49 |
GLUL,CLU,SPARCL1,MSI2,TNIK,NTM,SLC1A2,RORA,FGFR3,NFIA,APOE,SOX5,CDH20,COL5A3,PREX2,CPE,PCDH9,GPM6A,ZNRF3,TRPS1,BMPR1B,QKI,PTPRZ1,NRXN1,ATP1A2,NHSL1,CTNNA2,HIF3A,LSAMP,SLC1A3 |
1.804e-05 | -10.92 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 26 | 16828 | 49 |
CPE,LSAMP,AHCYL2,ATP1A2,CLU,CDH20,PREX2,SLC1A3,ATP13A4,PCDH9,FGFR3,MAML2,TRPS1,NKAIN3,SLC1A2,SPARCL1,QKI,RORA,SOX5,RYR3,HPSE2,TNIK,FBXL7,GPM6A,DTNA,GPC5 |
2.153e-05 | -10.75 | neuron differentiation | biological process | GO:0030182 | 1081 | 12 | 18204 | 49 |
PREX2,SLC1A3,GPM6A,TNIK,NTM,BMPR1B,PTPRZ1,RORA,NRXN1,CTNNA2,NFIA,APOE |
2.256e-05 | -10.70 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 11 | 19454 | 50 |
ATP1A2,APOE,SLC1A3,CTNNA2,GPM6A,LSAMP,SLC1A2,HEPACAM,CLU,NTM,TNIK |
2.531e-05 | -10.58 | multicellular organismal process | biological process | GO:0032501 | 6177 | 31 | 18204 | 49 |
SLC1A3,ATP1A2,CTNNA2,HIF3A,LSAMP,NRXN1,BMPR1B,PTPRZ1,QKI,PREX2,CPE,PCDH9,GPM6A,TRPS1,ZNRF3,CDH20,SOX5,PTGDS,SLC4A4,NFIA,APOE,RYR3,FGFR3,SLC1A2,RORA,DTNA,MSI2,TNIK,NTM,CLU,GLUL |
6.236e-05 | -9.68 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 23 | 16828 | 49 |
PREX2,CDH20,LSAMP,CPE,CLU,ATP1A2,AHCYL2,MAML2,FGFR3,PCDH9,ATP13A4,NKAIN3,SLC1A2,FBXL7,GPC5,GPM6A,QKI,SPARCL1,TNIK,HPSE2,RYR3,SOX5,RORA |
6.571e-05 | -9.63 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
6.571e-05 | -9.63 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
7.061e-05 | -9.56 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 2 | 18204 | 49 |
CLU,APOE |
7.061e-05 | -9.56 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.061e-05 | -9.56 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
7.070e-05 | -9.56 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 49 |
SLC1A3,ATP1A2,SLC1A2 |
7.567e-05 | -9.49 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 49 |
QKI,RYR3,HPSE2,MAML2,SOX5,PCDH9,RORA,FBXL7,GPC5,LSAMP,COL5A3,NKAIN3,SLC1A3,PREX2 |
7.567e-05 | -9.49 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 49 |
SLC1A3,PREX2,NKAIN3,LSAMP,COL5A3,GPC5,FBXL7,HPSE2,RYR3,MAML2,SOX5,PCDH9,RORA,QKI |
7.700e-05 | -9.47 | cell body | cellular component | GO:0044297 | 556 | 8 | 19108 | 49 |
ATP1A2,APOE,GLUL,NRXN1,SLC1A3,BMPR1B,GPM6A,SLC1A2 |
7.981e-05 | -9.44 | neuron development | biological process | GO:0048666 | 859 | 10 | 18204 | 49 |
BMPR1B,PTPRZ1,PREX2,SLC1A3,TNIK,GPM6A,NTM,CTNNA2,APOE,NRXN1 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
GPM6A,NTM,LSAMP |
8.364e-05 | -9.39 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 49 |
SLC1A3,ATP1A2,SLC4A4,SLC1A2 |
8.364e-05 | -9.39 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 49 |
SLC1A3,SLC1A2,SLC4A4,ATP1A2 |
9.447e-05 | -9.27 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 49 |
ATP1A2,SLC1A3,NRXN1 |
9.646e-05 | -9.25 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 9 | 16828 | 49 |
CPE,RYR3,HPSE2,PARD3B,MAML2,PCDH9,NRXN1,PTPRZ1,NPAS3 |
9.759e-05 | -9.23 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 9 | 16828 | 49 |
CPE,PARD3B,MAML2,HPSE2,RYR3,PCDH9,NRXN1,PTPRZ1,NPAS3 |
9.782e-05 | -9.23 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 17 | 16828 | 49 |
LSAMP,COL5A3,NKAIN3,PREX2,SLC1A3,PTPRZ1,SLC1A2,CDH20,SOX5,MAML2,RYR3,HPSE2,PCDH9,FGFR3,FBXL7,GPC5,GPM6A |
1.023e-04 | -9.19 | neuron projection | cellular component | GO:0043005 | 1331 | 12 | 19108 | 49 |
AHCYL2,GPM6A,DTNA,CTNNA2,SLC1A3,APOE,PCDH9,HEPACAM,ATP1A2,CLU,SLC1A2,BMPR1B |
1.057e-04 | -9.15 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.057e-04 | -9.15 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.104e-04 | -9.11 | proteoglycan binding | molecular function | GO:0043394 | 36 | 3 | 18094 | 47 |
COL5A3,APOE,HPSE2 |
1.275e-04 | -8.97 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 30 | 16828 | 49 |
NHSL1,CDH20,PREX2,SLC1A3,PARD3B,CLU,PAMR1,APOE,LSAMP,GLIS3,TRPS1,ZNRF3,FGFR3,PCDH9,MAML2,NPAS3,SLC1A2,PON2,PTPRZ1,NKAIN3,COL5A3,GPM6A,GPC5,NFIA,FBXL7,RORA,SOX5,HPSE2,RYR3,SPARCL1 |
1.342e-04 | -8.92 | mouth | COSMIC cancer mutations | mouth | 9004 | 39 | 16828 | 49 |
RORA,SOX5,RYR3,HPSE2,TNIK,QKI,GPM6A,DTNA,CST3,ZBTB20,GPC5,FBXL7,GLUL,COL5A3,NPAS3,SLC1A2,PTPRZ1,ATP13A4,ZNRF3,PCDH9,FGFR3,NTM,MAML2,NRXN1,HEPACAM,TRPS1,HIF3A,SLC4A4,PARD3B,CLU,ATP1A2,PAMR1,APOE,LSAMP,NHSL1,CDH20,SLC1A3,PREX2,PITPNC1 |
1.398e-04 | -8.88 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 8 | 16828 | 49 |
LSAMP,PCDH9,AHCYL2,SOX5,RYR3,NKAIN3,GPM6A,GPC5 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.565e-04 | -8.76 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,RYR3 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A3,SLC1A2 |
1.707e-04 | -8.68 | cell adhesion | biological process | GO:0007155 | 942 | 10 | 18204 | 49 |
HEPACAM,NRXN1,PARD3B,SPARCL1,CTNNA2,LSAMP,COL5A3,PCDH9,NTM,CDH20 |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A3,SLC1A2 |
1.967e-04 | -8.53 | protein import | biological process | GO:0017038 | 8 | 2 | 18204 | 49 |
CLU,APOE |
2.049e-04 | -8.49 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 33 | 16828 | 49 |
PAMR1,LSAMP,SLC4A4,PARD3B,ATP1A2,PITPNC1,NHSL1,CDH20,PREX2,ZNRF3,ATP13A4,FGFR3,PCDH9,MAML2,NTM,TRPS1,HEPACAM,HIF3A,NRXN1,GLUL,SLC1A2,PTPRZ1,QKI,RORA,SOX5,TNIK,RYR3,FBXL7,GPM6A,CST3,DTNA,ZBTB20,GPC5 |
2.216e-04 | -8.41 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 19 | 16828 | 49 |
GPM6A,GPC5,TRPS1,HIF3A,FBXL7,PCDH9,ZNRF3,ATP13A4,HPSE2,RYR3,MAML2,SOX5,SLC1A2,SLC1A3,PREX2,NKAIN3,PARD3B,CPE,LSAMP |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.496e-04 | -8.30 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 14 | 16828 | 49 |
TNIK,RYR3,MAML2,SOX5,FGFR3,PCDH9,ATP13A4,GPC5,DTNA,GPM6A,TRPS1,PARD3B,LSAMP,SLC1A3 |
2.655e-04 | -8.23 | synapse | cellular component | GO:0045202 | 1473 | 12 | 19108 | 49 |
DTNA,GPM6A,SLC1A3,NRXN1,PTPRZ1,QKI,CLU,SLC1A2,SPARCL1,TNIK,APOE,ATP1A2 |
2.660e-04 | -8.23 | central nervous system development | biological process | GO:0007417 | 995 | 10 | 18204 | 49 |
CTNNA2,ATP1A2,CLU,BMPR1B,SLC1A2,QKI,PTPRZ1,RORA,MSI2,PCDH9 |
2.806e-04 | -8.18 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 31 |
SLC4A4,SLC1A2,AHCYL2,SLC1A3 |
2.888e-04 | -8.15 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 20 |
SLC1A2,SLC1A3 |
3.013e-04 | -8.11 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 7 | 18204 | 49 |
CTNNA2,BMPR1B,PTPRZ1,PREX2,GPM6A,NRXN1,TNIK |
3.129e-04 | -8.07 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 16 | 16828 | 49 |
PCDH9,SOX5,MAML2,HPSE2,RYR3,FBXL7,GPM6A,GPC5,COL5A3,LSAMP,NKAIN3,CDH20,SLC1A2,SLC1A3,PREX2,PTPRZ1 |
3.129e-04 | -8.07 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 16 | 16828 | 49 |
PCDH9,RYR3,HPSE2,SOX5,MAML2,GPM6A,GPC5,FBXL7,COL5A3,LSAMP,CDH20,SLC1A2,PTPRZ1,PREX2,SLC1A3,NKAIN3 |
3.150e-04 | -8.06 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.205e-04 | -8.05 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 7 | 18204 | 49 |
NRXN1,CTNNA2,PREX2,TNIK,GPM6A,BMPR1B,PTPRZ1 |
3.244e-04 | -8.03 | bone | COSMIC cancer mutations | bone | 8157 | 36 | 16828 | 49 |
HPSE2,RYR3,TNIK,SOX5,RORA,QKI,SPARCL1,GPC5,ZBTB20,CST3,DTNA,GPM6A,GLUL,COL5A3,PTPRZ1,PON2,NPAS3,NKAIN3,MAML2,PCDH9,FGFR3,PTGDS,ATP13A4,NRXN1,GLIS3,HIF3A,TRPS1,ATP1A2,PARD3B,AHCYL2,SLC4A4,LSAMP,CPE,PAMR1,SLC1A3,PREX2 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
SLC1A2,RYR3,SOX5,PREX2 |
3.407e-04 | -7.98 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 7 | 18204 | 49 |
GPM6A,TNIK,PREX2,PTPRZ1,BMPR1B,NRXN1,CTNNA2 |
3.488e-04 | -7.96 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 18 | 16828 | 49 |
SLC4A4,CLU,ATP1A2,PARD3B,SLC1A2,NHSL1,NPAS3,PREX2,PTPRZ1,PITPNC1,FGFR3,PCDH9,ATP13A4,RYR3,QKI,DTNA,GPC5,NFIA |
3.844e-04 | -7.86 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.844e-04 | -7.86 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.898e-04 | -7.85 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 31 |
AHCYL2,SLC4A4 |
3.906e-04 | -7.85 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 49 |
TRPS1,SOX5,BMPR1B |
4.023e-04 | -7.82 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 3 | 19454 | 50 |
CPE,CLU,APOE |
4.118e-04 | -7.79 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 21 | 16828 | 49 |
CPE,PAMR1,BMPR1B,LSAMP,SLC4A4,CLU,PARD3B,PITPNC1,NPAS3,SLC1A3,PTPRZ1,PREX2,PCDH9,ZNRF3,HPSE2,RYR3,TNIK,FBXL7,DTNA,GPC5,MSI2 |
4.118e-04 | -7.79 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 21 | 16828 | 49 |
DTNA,GPC5,MSI2,FBXL7,PCDH9,ZNRF3,RYR3,HPSE2,TNIK,NPAS3,PTPRZ1,SLC1A3,PREX2,PITPNC1,SLC4A4,CLU,PARD3B,PAMR1,CPE,BMPR1B,LSAMP |
4.203e-04 | -7.77 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 2 | 19454 | 50 |
CLU,APOE |
4.218e-04 | -7.77 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 18 | 16828 | 49 |
ZNRF3,PCDH9,MAML2,SOX5,RYR3,HPSE2,GPM6A,GPC5,TRPS1,HIF3A,FBXL7,PARD3B,CPE,LSAMP,SLC1A2,SLC1A3,PREX2,NKAIN3 |
4.258e-04 | -7.76 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 7 | 16828 | 49 |
LSAMP,MAML2,RYR3,GPC5,GPM6A,ATP13A4,PCDH9 |
4.605e-04 | -7.68 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 49 |
SLC1A3,NRXN1 |
4.796e-04 | -7.64 | neuron projection development | biological process | GO:0031175 | 693 | 8 | 18204 | 49 |
PREX2,GPM6A,TNIK,NRXN1,BMPR1B,CTNNA2,APOE,PTPRZ1 |
4.928e-04 | -7.62 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 20 |
ATP13A4,ATP1A2 |
5.225e-04 | -7.56 | extracellular matrix | cellular component | GO:0031012 | 559 | 7 | 19108 | 49 |
PTPRZ1,APOE,HPSE2,CLU,GPC5,COL5A3,SPARCL1 |
5.281e-04 | -7.55 | external encapsulating structure | cellular component | GO:0030312 | 560 | 7 | 19108 | 49 |
COL5A3,SPARCL1,CLU,HPSE2,GPC5,PTPRZ1,APOE |
5.428e-04 | -7.52 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 49 |
NRXN1,SLC1A3,SLC1A2,ATP1A2 |
5.432e-04 | -7.52 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 2 | 18204 | 49 |
CLU,APOE |
5.776e-04 | -7.46 | C9 (complement C9) | protein interactions | 735 | 14 | 2 | 19454 | 50 |
APOE,CLU |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
GPM6A,CLU |
5.891e-04 | -7.44 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
6.327e-04 | -7.37 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 49 |
SLC4A4,ATP1A2 |
6.327e-04 | -7.37 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
6.356e-04 | -7.36 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 49 |
SLC1A2,ATP1A2,NRXN1,PREX2 |
6.518e-04 | -7.34 | cell population proliferation | biological process | GO:0008283 | 726 | 8 | 18204 | 49 |
GLUL,FGFR3,CLU,NFIA,ZNRF3,SOX5,HPSE2,RORA |
6.556e-04 | -7.33 | Ig_3 | pfam domains | PF13927 | 141 | 4 | 17795 | 50 |
FGFR3,HEPACAM,NTM,LSAMP |
6.654e-04 | -7.32 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 2 | 19454 | 50 |
CPE,CLU |
6.850e-04 | -7.29 | scalp | COSMIC cancer mutations | scalp | 2110 | 15 | 16828 | 49 |
SLC4A4,ATP1A2,COL5A3,LSAMP,PREX2,PTPRZ1,FGFR3,RORA,ATP13A4,NTM,SOX5,GPC5,NRXN1,TRPS1,NFIA |
7.003e-04 | -7.26 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 47 |
SLC1A2,SLC4A4,ATP13A4,ATP1A2,SLC1A3 |
7.170e-04 | -7.24 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 41 | 16828 | 49 |
NKAIN3,SLC1A2,PON2,NPAS3,PTPRZ1,COL5A3,BMPR1B,GLUL,NFIA,FBXL7,DTNA,GPM6A,GPC5,ZBTB20,RORA,TNIK,RYR3,HPSE2,SOX5,PITPNC1,CDH20,PREX2,SLC1A3,APOE,PAMR1,CPE,LSAMP,AHCYL2,SLC4A4,ATP1A2,PARD3B,HEPACAM,TRPS1,HIF3A,GLIS3,NRXN1,FGFR3,PCDH9,ZNRF3,ATP13A4,NTM |
7.170e-04 | -7.24 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 41 | 16828 | 49 |
LSAMP,CPE,PAMR1,APOE,PARD3B,ATP1A2,SLC4A4,AHCYL2,PITPNC1,PREX2,SLC1A3,CDH20,NTM,ATP13A4,ZNRF3,PCDH9,FGFR3,HIF3A,HEPACAM,TRPS1,NRXN1,GLIS3,BMPR1B,COL5A3,GLUL,NKAIN3,PTPRZ1,NPAS3,SLC1A2,PON2,SOX5,HPSE2,TNIK,RYR3,RORA,FBXL7,NFIA,ZBTB20,GPC5,GPM6A,DTNA |
7.454e-04 | -7.20 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 47 |
ATP1A2,SLC1A2,SLC4A4,SLC1A3 |
7.502e-04 | -7.20 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
NFIA,HPSE2,GPC5,NPAS3,PCDH9 |
7.502e-04 | -7.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 5 | 16828 | 49 |
GPC5,HPSE2,PCDH9,NPAS3,NFIA |
7.549e-04 | -7.19 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 6 | 19108 | 49 |
CLU,GPC5,COL5A3,SPARCL1,PTPRZ1,APOE |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
LSAMP,ZBTB20 |
8.133e-04 | -7.11 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 5 | 18204 | 49 |
SLC1A3,ATP1A2,SLC4A4,SLC1A2,APOE |
8.315e-04 | -7.09 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 2 | 18204 | 49 |
ATP1A2,APOE |
8.727e-04 | -7.04 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 7 | 18204 | 49 |
ATP13A4,RYR3,ZBTB20,APOE,SLC4A4,ATP1A2,SLC1A3 |
9.296e-04 | -6.98 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 16 | 16828 | 49 |
NHSL1,NPAS3,CDH20,PON2,PREX2,SLC1A3,PARD3B,CLU,PAMR1,APOE,NFIA,TRPS1,ZNRF3,FGFR3,RYR3,SPARCL1 |
9.296e-04 | -6.98 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 16 | 16828 | 49 |
TRPS1,NFIA,RYR3,FGFR3,ZNRF3,SPARCL1,SLC1A3,PREX2,PON2,CDH20,NHSL1,NPAS3,CLU,PARD3B,APOE,PAMR1 |
9.407e-04 | -6.97 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 2 | 18204 | 49 |
CLU,APOE |
9.407e-04 | -6.97 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 2 | 18204 | 49 |
CLU,APOE |
9.443e-04 | -6.97 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 22 | 16828 | 49 |
SLC4A4,PARD3B,ATP1A2,PITPNC1,NHSL1,PREX2,ZNRF3,FGFR3,PCDH9,MAML2,TRPS1,HIF3A,GLIS3,COL5A3,NPAS3,SLC1A2,PTPRZ1,TNIK,RYR3,NFIA,FBXL7,GPM6A |
9.444e-04 | -6.96 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 6 | 18094 | 47 |
ATP1A2,SLC1A2,SLC4A4,GPM6A,RYR3,SLC1A3 |
9.592e-04 | -6.95 | humerus | COSMIC cancer mutations | humerus | 546 | 7 | 16828 | 49 |
GPC5,GPM6A,NKAIN3,HIF3A,PARD3B,SOX5,AHCYL2 |
9.696e-04 | -6.94 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 6 | 18204 | 49 |
ATP13A4,RYR3,SLC4A4,ATP1A2,APOE,SLC1A3 |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
SOX5,PREX2,RYR3,SLC1A2,FGFR3 |
9.840e-04 | -6.92 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 2 | 18094 | 47 |
APOE,HPSE2 |
9.840e-04 | -6.92 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
9.985e-04 | -6.91 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 49 |
SOX5,TRPS1,BMPR1B |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
GPM6A,LSAMP,NTM |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.075e-03 | -6.84 | nodular | COSMIC cancer mutations | nodular | 1515 | 12 | 16828 | 49 |
CPE,ATP1A2,SLC4A4,PREX2,PTPRZ1,CDH20,NPAS3,SPARCL1,FGFR3,ATP13A4,HIF3A,GLIS3 |
1.079e-03 | -6.83 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 6 | 18204 | 49 |
SLC1A3,ATP13A4,RYR3,APOE,ATP1A2,SLC4A4 |
1.124e-03 | -6.79 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 7 | 18094 | 47 |
SLC1A3,ATP1A2,GPM6A,SLC1A2,ATP13A4,SLC4A4,RYR3 |
1.150e-03 | -6.77 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
1.158e-03 | -6.76 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 49 |
PTPRZ1,CTNNA2,BMPR1B,NRXN1,PREX2,SLC1A3 |
1.173e-03 | -6.75 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 47 |
SLC1A2,SLC4A4,SLC1A3 |
1.179e-03 | -6.74 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.179e-03 | -6.74 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 2 | 18204 | 49 |
CLU,APOE |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
NPAS3,HIF3A |
1.190e-03 | -6.73 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 5 | 19108 | 49 |
COL5A3,SPARCL1,CST3,CLU,APOE |
1.194e-03 | -6.73 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 50 |
NRXN1,CST3 |
1.196e-03 | -6.73 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 49 |
SOX5,FGFR3,NFIA,BMPR1B |
1.226e-03 | -6.70 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
1.261e-03 | -6.68 | behavior | biological process | GO:0007610 | 619 | 7 | 18204 | 49 |
NRXN1,PREX2,SLC1A3,SLC1A2,PTPRZ1,APOE,ATP1A2 |
1.283e-03 | -6.66 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 50 |
HIF3A,NPAS3 |
1.307e-03 | -6.64 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
1.307e-03 | -6.64 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.318e-03 | -6.63 | HTR2A (5-hydroxytryptamine receptor 2A) | protein interactions | 3356 | 21 | 2 | 19454 | 50 |
GLUL,PON2 |
1.383e-03 | -6.58 | trunk | COSMIC cancer mutations | trunk | 3554 | 20 | 16828 | 49 |
ATP1A2,LSAMP,CPE,PTPRZ1,PREX2,SLC1A3,NPAS3,CDH20,MAML2,SOX5,HPSE2,RYR3,ATP13A4,PCDH9,FGFR3,SPARCL1,NRXN1,GLIS3,HIF3A,TRPS1 |
1.443e-03 | -6.54 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
1.443e-03 | -6.54 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.443e-03 | -6.54 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.443e-03 | -6.54 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.499e-03 | -6.50 | neuronal cell body | cellular component | GO:0043025 | 489 | 6 | 19108 | 49 |
NRXN1,BMPR1B,SLC1A3,GPM6A,ATP1A2,APOE |
1.550e-03 | -6.47 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 49 |
FGFR3,SOX5,BMPR1B |
1.552e-03 | -6.47 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 13 | 19108 | 49 |
PTGDS,AHCYL2,NRXN1,CST3,APOE,ATP1A2,CLU,RYR3,ATP13A4,GLUL,COL5A3,FGFR3,SPARCL1 |
1.582e-03 | -6.45 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 50 |
MSI2,HPSE2 |
1.582e-03 | -6.45 | Rbm38 (RNA binding motif protein 38) | protein interactions | 56190 | 23 | 2 | 19454 | 50 |
MSI2,QKI |
1.584e-03 | -6.45 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 49 |
SLC1A3,ATP1A2 |
1.595e-03 | -6.44 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 3 | 18094 | 47 |
CST3,CLU,APOE |
1.614e-03 | -6.43 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
1.689e-03 | -6.38 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 49 |
TRPS1,NRXN1,GPC5,ATP13A4,RORA,FGFR3,SOX5,PTPRZ1,COL5A3,LSAMP,SLC4A4,ATP1A2 |
1.723e-03 | -6.36 | LNP1 (leukemia NUP98 fusion partner 1) | protein interactions | 348801 | 24 | 2 | 19454 | 50 |
AHCYL2,GLUL |
1.726e-03 | -6.36 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 38 |
ATP1A2,ATP13A4 |
1.757e-03 | -6.34 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 47 |
ATP1A2,ATP13A4 |
1.757e-03 | -6.34 | low-density lipoprotein particle receptor binding | molecular function | GO:0050750 | 24 | 2 | 18094 | 47 |
CLU,APOE |
1.757e-03 | -6.34 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 47 |
ATP1A2,ATP13A4 |
1.758e-03 | -6.34 | cell development | biological process | GO:0048468 | 2236 | 14 | 18204 | 49 |
APOE,CTNNA2,NRXN1,SLC1A3,CLU,QKI,PTPRZ1,RORA,BMPR1B,TNIK,GPM6A,NTM,PREX2,MSI2 |
1.774e-03 | -6.33 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 5 | 16828 | 49 |
GPM6A,AHCYL2,SOX5,GPC5,NKAIN3 |
1.781e-03 | -6.33 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 41 | 16828 | 49 |
PREX2,SLC1A3,NHSL1,CDH20,LSAMP,CPE,PAMR1,PARD3B,CLU,ATP1A2,SLC4A4,AHCYL2,TRPS1,HEPACAM,NRXN1,GLIS3,NTM,MAML2,PTGDS,ZNRF3,ATP13A4,FGFR3,PCDH9,PTPRZ1,NPAS3,SLC1A2,BMPR1B,COL5A3,GLUL,FBXL7,ZBTB20,MSI2,GPC5,DTNA,CST3,QKI,SOX5,RYR3,HPSE2,TNIK,RORA |
1.782e-03 | -6.33 | HS-GAG degradation | REACTOME pathways | R-HSA-2024096 | 21 | 2 | 10285 | 31 |
GPC5,HPSE2 |
1.808e-03 | -6.32 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 39 | 16828 | 49 |
MAML2,NTM,ZNRF3,ATP13A4,PCDH9,FGFR3,HIF3A,TRPS1,HEPACAM,NRXN1,CPE,PAMR1,PARD3B,CLU,ATP1A2,AHCYL2,SLC4A4,PITPNC1,PREX2,CDH20,SPARCL1,QKI,SOX5,TNIK,HPSE2,RYR3,RORA,FBXL7,NFIA,MSI2,GPC5,GPM6A,DTNA,CST3,BMPR1B,COL5A3,NKAIN3,PTPRZ1,NPAS3 |
1.831e-03 | -6.30 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 39 | 16828 | 49 |
NFIA,FBXL7,GPM6A,DTNA,CST3,MSI2,GPC5,SPARCL1,QKI,RORA,SOX5,HPSE2,TNIK,RYR3,NKAIN3,NPAS3,PTPRZ1,COL5A3,BMPR1B,TRPS1,HEPACAM,HIF3A,NRXN1,ZNRF3,ATP13A4,PCDH9,FGFR3,NTM,MAML2,PITPNC1,CDH20,PREX2,CPE,PAMR1,SLC4A4,AHCYL2,PARD3B,CLU,ATP1A2 |
1.848e-03 | -6.29 | cell surface | cellular component | GO:0009986 | 896 | 8 | 19108 | 49 |
FGFR3,SLC1A3,NRXN1,CLU,SLC1A2,GPC5,ATP1A2,SLC4A4 |
1.911e-03 | -6.26 | cell-cell junction | cellular component | GO:0005911 | 513 | 6 | 19108 | 49 |
CTNNA2,PARD3B,HEPACAM,ATP1A2,PCDH9,CDH20 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.960e-03 | -6.23 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 49 |
GPM6A,NRXN1,SPARCL1,APOE,NFIA |
1.987e-03 | -6.22 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 3 | 19454 | 50 |
GLUL,CLU,SPARCL1 |
2.013e-03 | -6.21 | high-density lipoprotein particle | cellular component | GO:0034364 | 26 | 2 | 19108 | 49 |
APOE,CLU |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
FGFR3,PREX2 |
2.047e-03 | -6.19 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.135e-03 | -6.15 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 33 | 16828 | 49 |
PCDH9,FGFR3,ATP13A4,MAML2,GLIS3,TRPS1,AHCYL2,SLC4A4,ATP1A2,CLU,APOE,CPE,PAMR1,LSAMP,CDH20,NHSL1,PREX2,SLC1A3,RORA,HPSE2,TNIK,RYR3,SOX5,QKI,GPM6A,GPC5,FBXL7,COL5A3,BMPR1B,PON2,SLC1A2,PTPRZ1,NKAIN3 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
CTNNA2,CDH20,DTNA |
2.161e-03 | -6.14 | cell projection | cellular component | GO:0042995 | 2398 | 14 | 19108 | 49 |
AHCYL2,CTNNA2,DTNA,GPM6A,NRXN1,SLC1A3,APOE,PCDH9,HEPACAM,ATP1A2,SLC1A2,CLU,GLUL,BMPR1B |
2.181e-03 | -6.13 | MBNL2 (muscleblind like splicing regulator 2) | protein interactions | 10150 | 27 | 2 | 19454 | 50 |
MSI2,QKI |
2.214e-03 | -6.11 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.217e-03 | -6.11 | glutamine biosynthesis | BIOCYC pathways | HUMAN_GLNSYN-PWY | 1 | 1 | 902 | 2 |
GLUL |
2.217e-03 | -6.11 | L-glutamine biosynthesis I | BIOCYC pathways | META_GLNSYN-PWY | 1 | 1 | 902 | 2 |
GLUL |
2.217e-03 | -6.11 | glutamate dependent acid resistance | BIOCYC pathways | HUMAN_PWY0-1305 | 1 | 1 | 902 | 2 |
GLUL |
2.220e-03 | -6.11 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 21 | 16828 | 49 |
PITPNC1,NPAS3,SLC1A2,PTPRZ1,PREX2,COL5A3,SLC4A4,PARD3B,ATP1A2,NFIA,TRPS1,HIF3A,FBXL7,GPM6A,GLIS3,ZNRF3,PCDH9,FGFR3,MAML2,RYR3,TNIK |
2.222e-03 | -6.11 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 49 |
PREX2,SLC1A2,NHSL1,PITPNC1,NFIA,CLU,ATP1A2,SLC4A4,FGFR3,ATP13A4,QKI |
2.222e-03 | -6.11 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 49 |
PITPNC1,PREX2,SLC1A2,NHSL1,CLU,ATP1A2,SLC4A4,NFIA,QKI,FGFR3,ATP13A4 |
2.227e-03 | -6.11 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 21 | 16828 | 49 |
ZNRF3,PCDH9,FGFR3,MAML2,TNIK,RYR3,NFIA,TRPS1,HIF3A,FBXL7,GLIS3,GPM6A,COL5A3,SLC4A4,PARD3B,ATP1A2,PITPNC1,NPAS3,SLC1A2,PTPRZ1,PREX2 |
2.247e-03 | -6.10 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 3 | 12186 | 42 |
CPE,APOE,GLIS3 |
2.250e-03 | -6.10 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 6 | 18204 | 49 |
ATP1A2,SLC4A4,APOE,ATP13A4,RYR3,SLC1A3 |
2.304e-03 | -6.07 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 22 | 16828 | 49 |
SLC4A4,PARD3B,COL5A3,NHSL1,CDH20,PTPRZ1,PREX2,ATP13A4,PTGDS,PCDH9,FGFR3,NTM,SOX5,RYR3,HPSE2,TNIK,GPM6A,ZBTB20,NFIA,TRPS1,FBXL7,HIF3A |
2.324e-03 | -6.06 | cellular homeostasis | biological process | GO:0019725 | 689 | 7 | 18204 | 49 |
ZBTB20,RYR3,SLC1A3,ATP13A4,APOE,ATP1A2,SLC4A4 |
2.328e-03 | -6.06 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 31 |
SLC1A2,SLC1A3 |
2.396e-03 | -6.03 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 23 |
ATP1A2,SLC4A4 |
2.396e-03 | -6.03 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 23 |
ATP1A2,SLC4A4 |
2.467e-03 | -6.00 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,RYR3 |
2.482e-03 | -6.00 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 6 | 18204 | 49 |
ATP1A2,SLC4A4,APOE,RYR3,ATP13A4,SLC1A3 |
2.564e-03 | -5.97 | lipoprotein particle receptor binding | molecular function | GO:0070325 | 29 | 2 | 18094 | 47 |
CLU,APOE |
2.564e-03 | -5.97 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
2.564e-03 | -5.97 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 49 |
CLU |
2.566e-03 | -5.97 | glial cell proliferation | biological process | GO:0014009 | 28 | 2 | 18204 | 49 |
CLU,NFIA |
2.566e-03 | -5.97 | positive regulation of oligodendrocyte differentiation | biological process | GO:0048714 | 28 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 50 |
NRXN1 |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.598e-03 | -5.95 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 47 |
APOE |
2.598e-03 | -5.95 | internal N(7)-methylguanine-containing RNA reader activity | molecular function | GO:0160089 | 1 | 1 | 18094 | 47 |
QKI |
2.645e-03 | -5.94 | tibia | COSMIC cancer mutations | tibia | 836 | 8 | 16828 | 49 |
LSAMP,NKAIN3,CPE,QKI,PREX2,TNIK,GPM6A,FGFR3 |
2.692e-03 | -5.92 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 29 | 16828 | 49 |
HEPACAM,TRPS1,HIF3A,GLIS3,NRXN1,PCDH9,FGFR3,ATP13A4,MAML2,PITPNC1,PREX2,CPE,SLC4A4,ATP1A2,PARD3B,FBXL7,GPM6A,GPC5,ZBTB20,SPARCL1,HPSE2,RYR3,TNIK,SOX5,NPAS3,PTPRZ1,COL5A3,BMPR1B,GLUL |
2.698e-03 | -5.92 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 3 | 19454 | 50 |
TRPS1,AHCYL2,NFIA |
2.699e-03 | -5.92 | beta-catenin binding | molecular function | GO:0008013 | 107 | 3 | 18094 | 47 |
CTNNA2,CDH20,RORA |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | STAR_dimer | interpro domains | IPR032377 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | Gln_synth_N_conserv_site | interpro domains | IPR027302 | 1 | 1 | 18521 | 50 |
GLUL |
2.700e-03 | -5.91 | Quaking_NLS | interpro domains | IPR032367 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | Gln_synth_gly_rich_site | interpro domains | IPR027303 | 1 | 1 | 18521 | 50 |
GLUL |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
RORA,RYR3,TNIK,HPSE2,QKI,GPM6A,ZBTB20,GPC5,NFIA,GLUL,BMPR1B,NPAS3,SLC1A2,PTPRZ1,NKAIN3,PTGDS,ZNRF3,PCDH9,MAML2,GLIS3,NRXN1,PARD3B,CPE,APOE,SLC1A3,PREX2,SOX5,SPARCL1,DTNA,CST3,FBXL7,COL5A3,PON2,ATP13A4,FGFR3,NTM,HEPACAM,TRPS1,HIF3A,AHCYL2,SLC4A4,CLU,ATP1A2,PAMR1,LSAMP,NHSL1,CDH20,PITPNC1 |
2.751e-03 | -5.90 | negative regulation of amyloid-beta formation | biological process | GO:1902430 | 29 | 2 | 18204 | 49 |
APOE,CLU |
2.751e-03 | -5.90 | postsynaptic membrane organization | biological process | GO:0001941 | 29 | 2 | 18204 | 49 |
APOE,NRXN1 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
QKI,RORA,TNIK,RYR3,HPSE2,NFIA,GPM6A,GPC5,ZBTB20,BMPR1B,GLUL,NKAIN3,SLC1A2,NPAS3,PTPRZ1,PCDH9,PTGDS,ZNRF3,MAML2,GLIS3,NRXN1,APOE,CPE,PARD3B,SLC1A3,PREX2,SPARCL1,SOX5,FBXL7,DTNA,CST3,COL5A3,PON2,FGFR3,ATP13A4,NTM,TRPS1,HEPACAM,HIF3A,PAMR1,LSAMP,SLC4A4,AHCYL2,CLU,ATP1A2,PITPNC1,CDH20,NHSL1 |
2.810e-03 | -5.87 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 50 |
MAML2 |
2.810e-03 | -5.87 | Gln-synt_N | pfam domains | PF03951 | 1 | 1 | 17795 | 50 |
GLUL |
2.810e-03 | -5.87 | STAR_dimer | pfam domains | PF16544 | 1 | 1 | 17795 | 50 |
QKI |
2.810e-03 | -5.87 | Quaking_NLS | pfam domains | PF16551 | 1 | 1 | 17795 | 50 |
QKI |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.827e-03 | -5.87 | glial cell differentiation | biological process | GO:0010001 | 219 | 4 | 18204 | 49 |
NFIA,QKI,PTPRZ1,CLU |
2.828e-03 | -5.87 | chemical homeostasis | biological process | GO:0048878 | 914 | 8 | 18204 | 49 |
SLC1A3,RORA,ZBTB20,ATP13A4,RYR3,APOE,ATP1A2,SLC4A4 |
2.834e-03 | -5.87 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 49 |
SOX5,RORA,NFIA |
2.834e-03 | -5.87 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 23 |
RYR3,ATP1A2,CST3 |
2.834e-03 | -5.87 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 23 |
ATP1A2,RYR3,CST3 |
2.842e-03 | -5.86 | metal ion binding | molecular function | GO:0046872 | 4239 | 20 | 18094 | 47 |
PCDH9,CPE,ATP13A4,PAMR1,ZBTB20,SLC1A3,BMPR1B,PON2,TRPS1,RORA,RYR3,SLC1A2,APOE,SPARCL1,NRXN1,ATP1A2,ZNRF3,DTNA,GLIS3,GLUL |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CDH20,CTNNA2 |
2.906e-03 | -5.84 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 3 | 16828 | 49 |
LSAMP,NKAIN3,GPM6A |
2.916e-03 | -5.84 | cell junction organization | biological process | GO:0034330 | 532 | 6 | 18204 | 49 |
SPARCL1,APOE,NFIA,GPM6A,NRXN1,CDH20 |
2.942e-03 | -5.83 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.991e-03 | -5.81 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
3.014e-03 | -5.80 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 31 |
FGFR3 |
3.041e-03 | -5.80 | - | gene3d domains | 1.20.5.4010 | 1 | 1 | 14470 | 44 |
QKI |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.057e-03 | -5.79 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 50 |
NRXN1,PCDH9 |
3.073e-03 | -5.78 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 7 | 18094 | 47 |
ATP1A2,GPM6A,ATP13A4,SLC1A2,SLC4A4,RYR3,SLC1A3 |
3.104e-03 | -5.78 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 46 | 16828 | 49 |
ATP13A4,FGFR3,NTM,TRPS1,HEPACAM,HIF3A,PAMR1,LSAMP,AHCYL2,SLC4A4,ATP1A2,CLU,PITPNC1,NHSL1,CDH20,SOX5,FBXL7,CST3,DTNA,MSI2,COL5A3,ZNRF3,PTGDS,PCDH9,MAML2,GLIS3,NRXN1,APOE,PARD3B,SLC1A3,PREX2,QKI,RORA,RYR3,HPSE2,TNIK,NFIA,GPM6A,ZBTB20,GPC5,BMPR1B,GLUL,NKAIN3,NPAS3,SLC1A2,PTPRZ1 |
3.140e-03 | -5.76 | negative regulation of amyloid precursor protein catabolic process | biological process | GO:1902992 | 31 | 2 | 18204 | 49 |
CLU,APOE |
3.177e-03 | -5.75 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 44 | 16828 | 49 |
PARD3B,CPE,PREX2,SLC1A3,MAML2,PCDH9,ZNRF3,NRXN1,GLIS3,BMPR1B,PTPRZ1,SLC1A2,NPAS3,NKAIN3,TNIK,RYR3,HPSE2,RORA,QKI,GPC5,ZBTB20,GPM6A,NFIA,CLU,ATP1A2,SLC4A4,AHCYL2,LSAMP,PAMR1,CDH20,NHSL1,PITPNC1,NTM,FGFR3,ATP13A4,HIF3A,TRPS1,COL5A3,PON2,SOX5,SPARCL1,MSI2,DTNA,FBXL7 |
3.204e-03 | -5.74 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 43 | 16828 | 49 |
PON2,COL5A3,DTNA,CST3,FBXL7,SOX5,SPARCL1,CDH20,NHSL1,PITPNC1,ATP1A2,SLC4A4,LSAMP,PAMR1,HIF3A,TRPS1,HEPACAM,NTM,FGFR3,ATP13A4,PTPRZ1,SLC1A2,NPAS3,GLUL,BMPR1B,GPC5,ZBTB20,GPM6A,NFIA,HPSE2,TNIK,RYR3,RORA,QKI,SLC1A3,PREX2,PARD3B,CPE,NRXN1,GLIS3,MAML2,PCDH9,ZNRF3 |
3.219e-03 | -5.74 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 49 |
COL5A3,SLC4A4,ATP13A4,NTM |
3.224e-03 | -5.74 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 50 |
PAMR1,SLC1A2 |
3.237e-03 | -5.73 | cervix | COSMIC cancer mutations | cervix | 11793 | 43 | 16828 | 49 |
CPE,PARD3B,SLC1A3,PREX2,MAML2,PCDH9,ZNRF3,NRXN1,GLIS3,BMPR1B,GLUL,PTPRZ1,SLC1A2,NPAS3,QKI,HPSE2,TNIK,RYR3,RORA,NFIA,GPC5,ZBTB20,GPM6A,LSAMP,PAMR1,ATP1A2,SLC4A4,PITPNC1,CDH20,NHSL1,NTM,FGFR3,ATP13A4,HIF3A,TRPS1,HEPACAM,COL5A3,PON2,SPARCL1,SOX5,FBXL7,CST3,DTNA |
3.249e-03 | -5.73 | VLDLR (very low density lipoprotein receptor) | protein interactions | 7436 | 33 | 2 | 19454 | 50 |
APOE,CLU |
3.253e-03 | -5.73 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 31 | 16828 | 49 |
PTPRZ1,SLC1A2,NPAS3,COL5A3,GLUL,FBXL7,NFIA,ZBTB20,CST3,QKI,RYR3,HPSE2,SOX5,RORA,PITPNC1,PREX2,CDH20,NHSL1,LSAMP,CLU,ATP1A2,PARD3B,SLC4A4,TRPS1,NRXN1,NTM,MAML2,FGFR3,PCDH9,ATP13A4,ZNRF3 |
3.253e-03 | -5.73 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 31 | 16828 | 49 |
PTPRZ1,SLC1A2,NPAS3,GLUL,COL5A3,ZBTB20,CST3,FBXL7,NFIA,RYR3,HPSE2,SOX5,RORA,QKI,PREX2,CDH20,NHSL1,PITPNC1,ATP1A2,CLU,PARD3B,SLC4A4,LSAMP,NRXN1,TRPS1,MAML2,NTM,PCDH9,FGFR3,ZNRF3,ATP13A4 |
3.344e-03 | -5.70 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
3.344e-03 | -5.70 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.344e-03 | -5.70 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 49 |
SOX5,BMPR1B |
3.394e-03 | -5.69 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 7 | 10285 | 31 |
SLC1A3,ATP13A4,SLC1A2,SLC4A4,RYR3,ATP1A2,AHCYL2 |
3.415e-03 | -5.68 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
FGFR3,PREX2 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.447e-03 | -5.67 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 42 |
CLU |
3.447e-03 | -5.67 | GLNA_1 | prosite domains | PS00180 | 1 | 1 | 12186 | 42 |
GLUL |
3.447e-03 | -5.67 | GLNA_ATP | prosite domains | PS00181 | 1 | 1 | 12186 | 42 |
GLUL |
3.447e-03 | -5.67 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 42 |
CLU |
3.465e-03 | -5.67 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 3 | 19454 | 50 |
APOE,CPE,CLU |
3.473e-03 | -5.66 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC4A4 |
3.476e-03 | -5.66 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 49 |
FGFR3,SOX5,NFIA,BMPR1B |
3.531e-03 | -5.65 | transporter activity | molecular function | GO:0005215 | 1211 | 9 | 18094 | 47 |
SLC1A3,PITPNC1,APOE,ATP13A4,SLC1A2,SLC4A4,GPM6A,ATP1A2,RYR3 |
3.548e-03 | -5.64 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 3 | 19454 | 50 |
APOE,PCDH9,CLU |
3.548e-03 | -5.64 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 10 | 16828 | 49 |
ATP1A2,ATP13A4,SPARCL1,CPE,PTPRZ1,PREX2,NPAS3,GLIS3,CDH20,HIF3A |
3.568e-03 | -5.64 | extracellular region | cellular component | GO:0005576 | 4350 | 20 | 19108 | 49 |
CPE,PAMR1,CST3,TNIK,APOE,ATP1A2,SLC4A4,LSAMP,CLU,HPSE2,COL5A3,FGFR3,SPARCL1,PON2,GLUL,PTPRZ1,PTGDS,NTM,GPM6A,GPC5 |
3.621e-03 | -5.62 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 41 | 16828 | 49 |
NHSL1,CDH20,PREX2,SLC1A3,AHCYL2,SLC4A4,PARD3B,CLU,ATP1A2,PAMR1,CPE,LSAMP,GLIS3,NRXN1,HEPACAM,TRPS1,ATP13A4,PTGDS,ZNRF3,PCDH9,FGFR3,MAML2,NTM,NPAS3,SLC1A2,PTPRZ1,GLUL,COL5A3,BMPR1B,DTNA,CST3,MSI2,ZBTB20,GPC5,FBXL7,RORA,SOX5,TNIK,HPSE2,RYR3,QKI |
3.637e-03 | -5.62 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.721e-03 | -5.59 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
3.769e-03 | -5.58 | negative regulation of amide metabolic process | biological process | GO:0034249 | 34 | 2 | 18204 | 49 |
CLU,APOE |
3.769e-03 | -5.58 | exploration behavior | biological process | GO:0035640 | 34 | 2 | 18204 | 49 |
ATP1A2,APOE |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.817e-03 | -5.57 | cation binding | molecular function | GO:0043169 | 4341 | 20 | 18094 | 47 |
ATP1A2,ZNRF3,APOE,SLC1A2,SPARCL1,NRXN1,RYR3,RORA,GLIS3,GLUL,DTNA,PAMR1,ZBTB20,ATP13A4,CPE,PCDH9,BMPR1B,TRPS1,PON2,SLC1A3 |
3.839e-03 | -5.56 | lipoprotein particle | cellular component | GO:1990777 | 36 | 2 | 19108 | 49 |
APOE,CLU |
3.839e-03 | -5.56 | plasma lipoprotein particle | cellular component | GO:0034358 | 36 | 2 | 19108 | 49 |
CLU,APOE |
3.857e-03 | -5.56 | ZNRF1 (zinc and ring finger 1) | protein interactions | 84937 | 36 | 2 | 19454 | 50 |
GLUL,ATP1A2 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
FGFR3,HEPACAM,NTM,LSAMP |
3.936e-03 | -5.54 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 21 | 16828 | 49 |
ZNRF3,RORA,FGFR3,MAML2,RYR3,SPARCL1,GLIS3,NFIA,TRPS1,PARD3B,CLU,PAMR1,APOE,COL5A3,NPAS3,NHSL1,CDH20,PON2,PREX2,PTPRZ1,SLC1A3 |
3.979e-03 | -5.53 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 5 | 19108 | 49 |
SPARCL1,TNIK,APOE,SLC1A2,GPM6A |
4.006e-03 | -5.52 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 6 | 18094 | 47 |
ATP1A2,SLC1A2,SLC4A4,GPM6A,RYR3,SLC1A3 |
4.052e-03 | -5.51 | glial cell projection | cellular component | GO:0097386 | 37 | 2 | 19108 | 49 |
GLUL,SLC1A2 |
4.070e-03 | -5.50 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 13 | 19108 | 49 |
SLC1A2,CLU,GLUL,BMPR1B,APOE,PCDH9,ATP1A2,HEPACAM,CTNNA2,DTNA,GPM6A,SLC1A3,AHCYL2 |
4.071e-03 | -5.50 | TRNAU1AP (tRNA selenocysteine 1 associated protein 1) | protein interactions | 54952 | 37 | 2 | 19454 | 50 |
ZBTB20,QKI |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
CST3,GPM6A |
4.127e-03 | -5.49 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 49 |
ATP1A2,RYR3,DTNA |
4.221e-03 | -5.47 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 38 |
NPAS3,HIF3A |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.257e-03 | -5.46 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 26 | 16828 | 49 |
ATP13A4,ZNRF3,MAML2,NTM,TRPS1,PAMR1,LSAMP,AHCYL2,SLC4A4,PARD3B,ATP1A2,CLU,CDH20,SLC1A3,SOX5,HPSE2,RYR3,FBXL7,GPM6A,CST3,DTNA,GPC5,COL5A3,NKAIN3,NPAS3,PTPRZ1 |
4.257e-03 | -5.46 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 26 | 16828 | 49 |
MAML2,NTM,ZNRF3,ATP13A4,TRPS1,PARD3B,ATP1A2,CLU,AHCYL2,SLC4A4,LSAMP,PAMR1,SLC1A3,CDH20,SOX5,RYR3,HPSE2,GPC5,GPM6A,DTNA,CST3,FBXL7,COL5A3,PTPRZ1,NPAS3,NKAIN3 |
4.258e-03 | -5.46 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 3 | 19454 | 50 |
TRPS1,QKI,NFIA |
4.281e-03 | -5.45 | regulation of synapse organization | biological process | GO:0050807 | 246 | 4 | 18204 | 49 |
GPM6A,NRXN1,APOE,CTNNA2 |
4.290e-03 | -5.45 | Pcbp1 (poly(rC) binding protein 1) | protein interactions | 23983 | 38 | 2 | 19454 | 50 |
QKI,MSI2 |
4.290e-03 | -5.45 | MMP3 (matrix metallopeptidase 3) | protein interactions | 4314 | 38 | 2 | 19454 | 50 |
CLU,APOE |
4.391e-03 | -5.43 | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | 34 | 2 | 16828 | 49 |
FGFR3,QKI |
4.432e-03 | -5.42 | L-glutamate and L-glutamine biosynthesis | BIOCYC pathways | META_PWY-5505 | 2 | 1 | 902 | 2 |
GLUL |
4.451e-03 | -5.41 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
4.451e-03 | -5.41 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.493e-03 | -5.41 | protein-lipid complex | cellular component | GO:0032994 | 39 | 2 | 19108 | 49 |
APOE,CLU |
4.602e-03 | -5.38 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 6 | 19454 | 50 |
AHCYL2,CLU,FGFR3,NHSL1,DTNA,TNIK |
4.662e-03 | -5.37 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 4 | 18204 | 49 |
NRXN1,GPM6A,CTNNA2,APOE |
4.691e-03 | -5.36 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
4.745e-03 | -5.35 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 42 |
NPAS3,HIF3A |
4.912e-03 | -5.32 | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | 36 | 2 | 16828 | 49 |
FGFR3,QKI |
4.918e-03 | -5.31 | cell differentiation | biological process | GO:0030154 | 3645 | 18 | 18204 | 49 |
SLC1A3,SOX5,FGFR3,NRXN1,NHSL1,CTNNA2,APOE,NFIA,MSI2,PREX2,NTM,GPM6A,TNIK,BMPR1B,RORA,PTPRZ1,QKI,CLU |
4.936e-03 | -5.31 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 49 |
SLC1A3,ATP1A2 |
4.936e-03 | -5.31 | positive regulation of nitric oxide biosynthetic process | biological process | GO:0045429 | 39 | 2 | 18204 | 49 |
CLU,APOE |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
NTM,CPE,GPM6A |
4.963e-03 | -5.31 | cellular developmental process | biological process | GO:0048869 | 3648 | 18 | 18204 | 49 |
NRXN1,FGFR3,CTNNA2,NHSL1,APOE,NFIA,SLC1A3,SOX5,CLU,MSI2,PREX2,NTM,TNIK,GPM6A,BMPR1B,RORA,PTPRZ1,QKI |
4.977e-03 | -5.30 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 21 | 16828 | 49 |
SLC1A3,PTPRZ1,PREX2,CDH20,PON2,NPAS3,NHSL1,APOE,COL5A3,PAMR1,CLU,PARD3B,TRPS1,NFIA,GLIS3,SPARCL1,RYR3,MAML2,FGFR3,ZNRF3,RORA |
5.029e-03 | -5.29 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 5 | 18204 | 49 |
SLC1A2,APOE,DTNA,SLC1A3,NRXN1 |
5.029e-03 | -5.29 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 5 | 18204 | 49 |
SLC1A3,DTNA,NRXN1,APOE,SLC1A2 |
5.122e-03 | -5.27 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 49 |
APOE |
5.122e-03 | -5.27 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 49 |
APOE |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.184e-03 | -5.26 | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | 37 | 2 | 16828 | 49 |
QKI,FGFR3 |
5.187e-03 | -5.26 | positive regulation of nitric oxide metabolic process | biological process | GO:1904407 | 40 | 2 | 18204 | 49 |
CLU,APOE |
5.188e-03 | -5.26 | ammonia ligase activity | molecular function | GO:0016211 | 2 | 1 | 18094 | 47 |
GLUL |
5.188e-03 | -5.26 | glutamine synthetase activity | molecular function | GO:0004356 | 2 | 1 | 18094 | 47 |
GLUL |
5.188e-03 | -5.26 | heparanase activity | molecular function | GO:0030305 | 2 | 1 | 18094 | 47 |
HPSE2 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
DTNA,FGFR3,CDH20 |
5.322e-03 | -5.24 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.366e-03 | -5.23 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
5.376e-03 | -5.23 | glutamine biosynthetic process | biological process | GO:0006542 | 2 | 1 | 18204 | 49 |
GLUL |
5.376e-03 | -5.23 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 49 |
FGFR3 |
5.376e-03 | -5.23 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 49 |
CLU |
5.376e-03 | -5.23 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 49 |
ZNRF3 |
5.376e-03 | -5.23 | negative regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905869 | 2 | 1 | 18204 | 49 |
QKI |
5.376e-03 | -5.23 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 49 |
APOE |
5.376e-03 | -5.23 | myofibroblast contraction | biological process | GO:1990764 | 2 | 1 | 18204 | 49 |
QKI |
5.377e-03 | -5.23 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 7 | 19108 | 49 |
NRXN1,BMPR1B,SLC1A3,GPM6A,CLU,ATP1A2,APOE |
5.386e-03 | -5.22 | membrane | cellular component | GO:0016020 | 9220 | 33 | 19108 | 49 |
PON2,BMPR1B,GLUL,ATP13A4,HPSE2,CLU,SLC1A2,HEPACAM,ATP1A2,CST3,SLC1A3,NTM,PARD3B,PTPRZ1,FGFR3,LSAMP,RYR3,NKAIN3,SLC4A4,HIF3A,CPE,TNIK,APOE,PCDH9,NRXN1,CTNNA2,GPM6A,DTNA,GPC5,PREX2,ZNRF3,PTGDS,CDH20 |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Gln_synth_cat_dom | interpro domains | IPR008146 | 2 | 1 | 18521 | 50 |
GLUL |
5.392e-03 | -5.22 | Glyco_hydro_79 | interpro domains | IPR005199 | 2 | 1 | 18521 | 50 |
HPSE2 |
5.392e-03 | -5.22 | Gln_synt_N | interpro domains | IPR008147 | 2 | 1 | 18521 | 50 |
GLUL |
5.392e-03 | -5.22 | Gln_synt_N_sf | interpro domains | IPR036651 | 2 | 1 | 18521 | 50 |
GLUL |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3B |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Paraoxonase2 | interpro domains | IPR008364 | 2 | 1 | 18521 | 50 |
PON2 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.432e-03 | -5.22 | Ig_I-set | interpro domains | IPR013098 | 132 | 3 | 18521 | 50 |
NTM,LSAMP,FGFR3 |
5.440e-03 | -5.21 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 7 | 18204 | 49 |
SLC1A2,SLC1A3,GPM6A,ATP1A2,SLC4A4,RYR3,ATP13A4 |
5.461e-03 | -5.21 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | 38 | 2 | 16828 | 49 |
QKI,FGFR3 |
5.517e-03 | -5.20 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 3 | 7161 | 23 |
SLC1A2,GLUL,SLC1A3 |
5.517e-03 | -5.20 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 3 | 7161 | 23 |
SLC1A2,GLUL,SLC1A3 |
5.572e-03 | -5.19 | tau protein binding | molecular function | GO:0048156 | 43 | 2 | 18094 | 47 |
APOE,CLU |
5.612e-03 | -5.18 | Gln-synt_C | pfam domains | PF00120 | 2 | 1 | 17795 | 50 |
GLUL |
5.612e-03 | -5.18 | Glyco_hydro_79n | pfam domains | PF03662 | 2 | 1 | 17795 | 50 |
HPSE2 |
5.612e-03 | -5.18 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 50 |
PARD3B |
5.612e-03 | -5.18 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 50 |
ZNRF3 |
5.612e-03 | -5.18 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 50 |
CLU |
5.696e-03 | -5.17 | UPK2 (uroplakin 2) | protein interactions | 7379 | 141 | 3 | 19454 | 50 |
PCDH9,PON2,CTNNA2 |
5.706e-03 | -5.17 | triglyceride homeostasis | biological process | GO:0070328 | 42 | 2 | 18204 | 49 |
RORA,APOE |
5.718e-03 | -5.16 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 47 |
SLC1A2,SLC4A4,ATP13A4,ATP1A2,SLC1A3 |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
ATP1A2,DTNA,RYR3 |
5.890e-03 | -5.13 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 5 | 18204 | 49 |
APOE,SLC1A2,NRXN1,SLC1A3,DTNA |
5.974e-03 | -5.12 | acylglycerol homeostasis | biological process | GO:0055090 | 43 | 2 | 18204 | 49 |
RORA,APOE |
6.004e-03 | -5.12 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 5 | 18204 | 49 |
RYR3,SLC1A3,ATP13A4,APOE,ATP1A2 |
6.018e-03 | -5.11 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 4 | 18204 | 49 |
SLC1A3,GLUL,PTGDS,QKI |
6.064e-03 | -5.11 | I-set | pfam domains | PF07679 | 132 | 3 | 17795 | 50 |
NTM,LSAMP,FGFR3 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.073e-03 | -5.10 | Glutamine synthetase, N-terminal domain | gene3d domains | 3.10.20.70 | 2 | 1 | 14470 | 44 |
GLUL |
6.107e-03 | -5.10 | axon | cellular component | GO:0030424 | 650 | 6 | 19108 | 49 |
CTNNA2,SLC1A2,GPM6A,DTNA,PCDH9,HEPACAM |
6.121e-03 | -5.10 | blood vessel morphogenesis | biological process | GO:0048514 | 435 | 5 | 18204 | 49 |
GLUL,QKI,APOE,RORA,HIF3A |
6.127e-03 | -5.10 | cell-cell signaling | biological process | GO:0007267 | 822 | 7 | 18204 | 49 |
APOE,SLC1A2,FGFR3,NRXN1,SLC1A3,CPE,DTNA |
6.254e-03 | -5.07 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 4 | 18204 | 49 |
PTGDS,SLC1A3,GLUL,QKI |
6.334e-03 | -5.06 | gliogenesis | biological process | GO:0042063 | 275 | 4 | 18204 | 49 |
CLU,NFIA,PTPRZ1,QKI |
6.414e-03 | -5.05 | learning or memory | biological process | GO:0007611 | 276 | 4 | 18204 | 49 |
PTPRZ1,APOE,ATP1A2,NRXN1 |
6.454e-03 | -5.04 | leg | COSMIC cancer mutations | leg | 969 | 8 | 16828 | 49 |
PTPRZ1,ZBTB20,HIF3A,SLC4A4,FGFR3,ATP13A4,NTM,COL5A3 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
GPM6A,PTPRZ1 |
6.527e-03 | -5.03 | acidic amino acid transport | biological process | GO:0015800 | 45 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
6.550e-03 | -5.03 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 44 |
NPAS3,HIF3A |
6.588e-03 | -5.02 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC4A4 |
6.588e-03 | -5.02 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 49 |
ZBTB20,SLC4A4,APOE |
6.634e-03 | -5.02 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 50 |
SOX5,TNIK,NFIA |
6.645e-03 | -5.01 | GABA shunt | BIOCYC pathways | HUMAN_GLUDEG-I-PWY | 3 | 1 | 902 | 2 |
GLUL |
6.684e-03 | -5.01 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC4A4 |
6.783e-03 | -4.99 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 42 |
ATP1A2,ATP13A4 |
6.812e-03 | -4.99 | receptor clustering | biological process | GO:0043113 | 46 | 2 | 18204 | 49 |
APOE,NRXN1 |
6.812e-03 | -4.99 | regulation of oligodendrocyte differentiation | biological process | GO:0048713 | 46 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
6.812e-03 | -4.99 | positive regulation of glial cell differentiation | biological process | GO:0045687 | 46 | 2 | 18204 | 49 |
PTPRZ1,QKI |
6.882e-03 | -4.98 | GS_CATALYTIC | prosite domains | PS51987 | 2 | 1 | 12186 | 42 |
GLUL |
6.882e-03 | -4.98 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.882e-03 | -4.98 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.882e-03 | -4.98 | GS_BETA_GRASP | prosite domains | PS51986 | 2 | 1 | 12186 | 42 |
GLUL |
6.928e-03 | -4.97 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 6 | 18204 | 49 |
ATP13A4,SLC1A3,RYR3,GPM6A,SLC4A4,ATP1A2 |
6.932e-03 | -4.97 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 15 | 16828 | 49 |
RORA,ZNRF3,FGFR3,MAML2,RYR3,SPARCL1,GLIS3,NFIA,PARD3B,COL5A3,APOE,NPAS3,PON2,PTPRZ1,PREX2 |
6.932e-03 | -4.97 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 15 | 16828 | 49 |
SPARCL1,FGFR3,ZNRF3,RORA,RYR3,MAML2,NFIA,GLIS3,APOE,COL5A3,PARD3B,PON2,NPAS3,PREX2,PTPRZ1 |
7.064e-03 | -4.95 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 4 | 19454 | 50 |
NFIA,TRPS1,QKI,SOX5 |
7.135e-03 | -4.94 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
7.399e-03 | -4.91 | regulation of amyloid-beta formation | biological process | GO:1902003 | 48 | 2 | 18204 | 49 |
CLU,APOE |
7.404e-03 | -4.91 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 49 |
APOE,CDH20,RYR3,SOX5 |
7.519e-03 | -4.89 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 49 |
CTNNA2,SLC1A3,NRXN1 |
7.592e-03 | -4.88 | third_ventricle | COSMIC cancer mutations | third_ventricle | 45 | 2 | 16828 | 49 |
QKI,FGFR3 |
7.617e-03 | -4.88 | LINGO1 (leucine rich repeat and Ig domain containing 1) | protein interactions | 84894 | 51 | 2 | 19454 | 50 |
NTM,PON2 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.639e-03 | -4.87 | PARAOXONASE2 | prints domains | PR01787 | 2 | 1 | 5227 | 20 |
PON2 |
7.640e-03 | -4.87 | synaptic signaling | biological process | GO:0099536 | 459 | 5 | 18204 | 49 |
APOE,SLC1A2,NRXN1,SLC1A3,DTNA |
7.674e-03 | -4.87 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 20 |
ATP13A4,ATP1A2 |
7.688e-03 | -4.87 | Retinoid metabolism and transport | REACTOME pathways | R-HSA-975634 | 44 | 2 | 10285 | 31 |
APOE,GPC5 |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 50 |
NRXN1 |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 50 |
PTGDS |
7.700e-03 | -4.87 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 49 |
QKI,FGFR3,GPC5 |
7.762e-03 | -4.86 | anchoring junction | cellular component | GO:0070161 | 902 | 7 | 19108 | 49 |
FGFR3,CTNNA2,HEPACAM,PARD3B,ATP1A2,PCDH9,CDH20 |
7.773e-03 | -4.86 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 47 |
PTGDS |
7.773e-03 | -4.86 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | acid-ammonia (or amide) ligase activity | molecular function | GO:0016880 | 3 | 1 | 18094 | 47 |
GLUL |
7.773e-03 | -4.86 | acyl-L-homoserine-lactone lactonohydrolase activity | molecular function | GO:0102007 | 3 | 1 | 18094 | 47 |
PON2 |
7.773e-03 | -4.86 | lactonohydrolase activity | molecular function | GO:0046573 | 3 | 1 | 18094 | 47 |
PON2 |
7.773e-03 | -4.86 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 47 |
SLC1A2 |
7.806e-03 | -4.85 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 38 |
CLU |
7.806e-03 | -4.85 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 38 |
CLU |
7.806e-03 | -4.85 | Gln-synt_C | smart domains | SM01230 | 2 | 1 | 9717 | 38 |
GLUL |
7.928e-03 | -4.84 | TYRO3 (TYRO3 protein tyrosine kinase) | protein interactions | 7301 | 159 | 3 | 19454 | 50 |
SLC1A3,APOE,CLU |
7.942e-03 | -4.84 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 30 | 16828 | 49 |
CDH20,NHSL1,SLC1A3,PREX2,APOE,CPE,PAMR1,LSAMP,AHCYL2,SLC4A4,CLU,ATP1A2,GLIS3,FGFR3,PCDH9,ATP13A4,MAML2,NKAIN3,PON2,SLC1A2,COL5A3,BMPR1B,FBXL7,GPM6A,GPC5,QKI,RORA,HPSE2,RYR3,SOX5 |
7.987e-03 | -4.83 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 49 |
ATP1A2,SLC1A2,RORA,SLC1A3,RYR3 |
8.054e-03 | -4.82 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 49 |
ATP1A2 |
8.054e-03 | -4.82 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 49 |
NRXN1 |
8.054e-03 | -4.82 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 49 |
CTNNA2 |
8.054e-03 | -4.82 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 49 |
APOE |
8.065e-03 | -4.82 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
8.078e-03 | -4.82 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Arylesterase | interpro domains | IPR002640 | 3 | 1 | 18521 | 50 |
PON2 |
8.078e-03 | -4.82 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.157e-03 | -4.81 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 18 | 16828 | 49 |
ZBTB20,GPC5,GPM6A,SPARCL1,SOX5,MAML2,TNIK,RYR3,HPSE2,PCDH9,PTPRZ1,PREX2,NHSL1,PON2,PAMR1,COL5A3,ATP1A2,SLC4A4 |
8.206e-03 | -4.80 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 50 |
ZBTB20,AHCYL2 |
8.206e-03 | -4.80 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 18 | 16828 | 49 |
SLC4A4,ATP1A2,COL5A3,PAMR1,PON2,NHSL1,PREX2,PTPRZ1,PCDH9,TNIK,RYR3,HPSE2,SOX5,MAML2,SPARCL1,GPM6A,GPC5,ZBTB20 |
8.320e-03 | -4.79 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
8.365e-03 | -4.78 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
8.406e-03 | -4.78 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 50 |
MAML2 |
8.406e-03 | -4.78 | Arylesterase | pfam domains | PF01731 | 3 | 1 | 17795 | 50 |
PON2 |
8.406e-03 | -4.78 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.406e-03 | -4.78 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 50 |
HIF3A |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.447e-03 | -4.77 | ion binding | molecular function | GO:0043167 | 6007 | 24 | 18094 | 47 |
TNIK,ZBTB20,ATP13A4,BMPR1B,PON2,SLC1A3,FGFR3,ATP1A2,ZNRF3,GLIS3,CPE,PCDH9,PAMR1,PTGDS,PITPNC1,TRPS1,RORA,RYR3,SLC1A2,APOE,SPARCL1,NRXN1,DTNA,GLUL |
8.525e-03 | -4.76 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 49 |
BMPR1B,NFIA,GPM6A |
8.613e-03 | -4.75 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 20 | 16828 | 49 |
SPARCL1,TNIK,RYR3,SOX5,PCDH9,FGFR3,ZNRF3,ATP13A4,HIF3A,TRPS1,NFIA,GPC5,NRXN1,DTNA,GLIS3,LSAMP,COL5A3,CPE,ATP1A2,PTPRZ1 |
8.638e-03 | -4.75 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.638e-03 | -4.75 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.638e-03 | -4.75 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.736e-03 | -4.74 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 20 |
CST3,SLC1A2 |
8.771e-03 | -4.74 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
8.814e-03 | -4.73 | AMPH (amphiphysin) | protein interactions | 273 | 55 | 2 | 19454 | 50 |
GLUL,GPM6A |
8.962e-03 | -4.71 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
8.979e-03 | -4.71 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 49 |
SLC1A2,SLC4A4,SLC1A3 |
9.061e-03 | -4.70 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 30 | 16828 | 49 |
PAMR1,CPE,LSAMP,AHCYL2,CLU,PARD3B,CDH20,NHSL1,SLC1A3,PREX2,PCDH9,ATP13A4,MAML2,GLIS3,COL5A3,BMPR1B,NKAIN3,SLC1A2,PON2,PTPRZ1,QKI,SPARCL1,RORA,TNIK,HPSE2,RYR3,SOX5,FBXL7,GPM6A,GPC5 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 44 |
MAML2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.095e-03 | -4.70 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 44 |
AHCYL2 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
NRXN1,SLC1A2,GPM6A |
9.290e-03 | -4.68 | negative regulation of supramolecular fiber organization | biological process | GO:1902904 | 161 | 3 | 18204 | 49 |
APOE,CTNNA2,CLU |
9.302e-03 | -4.68 | lipid transfer activity | molecular function | GO:0120013 | 56 | 2 | 18094 | 47 |
PITPNC1,APOE |
9.442e-03 | -4.66 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 50 |
NRXN1,CTNNA2 |
9.565e-03 | -4.65 | export from cell | biological process | GO:0140352 | 485 | 5 | 18204 | 49 |
CPE,NRXN1,PTGDS,SLC4A4,ATP1A2 |
9.616e-03 | -4.64 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 49 |
SLC1A3,PREX2,PARD3B,APOE,CPE,NRXN1,GLIS3,MAML2,PCDH9,ZNRF3,PTGDS,PTPRZ1,SLC1A2,NPAS3,NKAIN3,GLUL,BMPR1B,GPC5,ZBTB20,GPM6A,NFIA,HPSE2,TNIK,RYR3,RORA,QKI,CDH20,NHSL1,PITPNC1,CLU,ATP1A2,SLC4A4,AHCYL2,LSAMP,PAMR1,HIF3A,HEPACAM,TRPS1,NTM,FGFR3,ATP13A4,PON2,COL5A3,MSI2,DTNA,FBXL7,SOX5,SPARCL1 |
9.625e-03 | -4.64 | intermembrane lipid transfer | biological process | GO:0120009 | 55 | 2 | 18204 | 49 |
APOE,PITPNC1 |
9.625e-03 | -4.64 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
9.625e-03 | -4.64 | regulation of amyloid precursor protein catabolic process | biological process | GO:1902991 | 55 | 2 | 18204 | 49 |
CLU,APOE |
9.630e-03 | -4.64 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 4 | 19454 | 50 |
DTNA,TNIK,CTNNA2,NHSL1 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
CDH20,NHSL1,PITPNC1,CLU,ATP1A2,AHCYL2,SLC4A4,LSAMP,PAMR1,HIF3A,TRPS1,HEPACAM,NTM,FGFR3,ATP13A4,PON2,COL5A3,MSI2,DTNA,CST3,FBXL7,SOX5,SPARCL1,PREX2,SLC1A3,PARD3B,APOE,CPE,NRXN1,GLIS3,MAML2,PCDH9,ZNRF3,PTGDS,PTPRZ1,SLC1A2,NPAS3,NKAIN3,GLUL,BMPR1B,GPC5,ZBTB20,GPM6A,NFIA,RYR3,HPSE2,TNIK,RORA,QKI |
9.709e-03 | -4.63 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 11 | 19454 | 50 |
BMPR1B,PARD3B,FGFR3,AHCYL2,NFIA,MSI2,ZBTB20,DTNA,QKI,TRPS1,PON2 |
9.763e-03 | -4.63 | HOXB6 (homeobox B6) | protein interactions | 3216 | 58 | 2 | 19454 | 50 |
AHCYL2,GLUL |
9.818e-03 | -4.62 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 9 | 16828 | 49 |
GPM6A,TRPS1,HPSE2,RYR3,TNIK,NTM,FGFR3,ATP13A4,PAMR1 |
9.818e-03 | -4.62 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 9 | 16828 | 49 |
GPM6A,TRPS1,HPSE2,TNIK,RYR3,NTM,FGFR3,ATP13A4,PAMR1 |
9.929e-03 | -4.61 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 49 |
SLC1A3,ATP1A2,SLC1A2 |
1.001e-02 | -4.60 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 6 | 18094 | 47 |
SLC1A3,RYR3,SLC4A4,SLC1A2,GPM6A,ATP1A2 |
1.002e-02 | -4.60 | Znf_NHR/GATA | interpro domains | IPR013088 | 56 | 2 | 18521 | 50 |
TRPS1,RORA |
1.009e-02 | -4.60 | VEGFA (vascular endothelial growth factor A) | protein interactions | 7422 | 59 | 2 | 19454 | 50 |
PTPRZ1,CLU |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,CDH20,DTNA |
1.022e-02 | -4.58 | collagen type V trimer | cellular component | GO:0005588 | 4 | 1 | 19108 | 49 |
COL5A3 |
1.022e-02 | -4.58 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 49 |
APOE |
1.023e-02 | -4.58 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 31 |
SLC1A2,SLC1A3 |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.025e-02 | -4.58 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 8 | 18204 | 49 |
ATP1A2,NFIA,RYR3,FGFR3,BMPR1B,SLC1A2,SLC1A3,SOX5 |
1.029e-02 | -4.58 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
1.030e-02 | -4.58 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 42 |
GPM6A |
1.030e-02 | -4.58 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 42 |
CTNNA2 |
1.030e-02 | -4.58 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 42 |
AHCYL2 |
1.030e-02 | -4.58 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 42 |
GPM6A |
1.030e-02 | -4.58 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 42 |
AHCYL2 |
1.031e-02 | -4.57 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 49 |
SLC1A2,ATP1A2 |
1.032e-02 | -4.57 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 31 |
SLC1A3,AHCYL2,SLC4A4,SLC1A2 |
1.035e-02 | -4.57 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 1 | 18094 | 47 |
APOE |
1.035e-02 | -4.57 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 47 |
RYR3 |
1.042e-02 | -4.56 | ITGA8 (integrin subunit alpha 8) | protein interactions | 8516 | 60 | 2 | 19454 | 50 |
ZNRF3,CLU |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DTNA,FGFR3 |
1.055e-02 | -4.55 | cognition | biological process | GO:0050890 | 319 | 4 | 18204 | 49 |
APOE,PTPRZ1,ATP1A2,NRXN1 |
1.061e-02 | -4.55 | GATA3 (GATA binding protein 3) | protein interactions | 2625 | 177 | 3 | 19454 | 50 |
NFIA,TRPS1,QKI |
1.072e-02 | -4.54 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 49 |
PTGDS |
1.072e-02 | -4.54 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 49 |
CST3 |
1.072e-02 | -4.54 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 49 |
CLU |
1.072e-02 | -4.54 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 49 |
CPE |
1.072e-02 | -4.54 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 49 |
BMPR1B |
1.072e-02 | -4.54 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 49 |
PTGDS |
1.072e-02 | -4.54 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 49 |
SOX5 |
1.072e-02 | -4.54 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 49 |
APOE |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 50 |
APOE |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.082e-02 | -4.53 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 49 |
FGFR3,TRPS1,SOX5,BMPR1B,NFIA |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
GLUL,BMPR1B,SLC1A2,NPAS3,PTPRZ1,NKAIN3,RORA,RYR3,TNIK,HPSE2,QKI,GPM6A,GPC5,ZBTB20,NFIA,PARD3B,APOE,CPE,PREX2,SLC1A3,PCDH9,PTGDS,ZNRF3,MAML2,GLIS3,NRXN1,COL5A3,PON2,SOX5,SPARCL1,DTNA,CST3,MSI2,FBXL7,AHCYL2,SLC4A4,ATP1A2,CLU,PAMR1,LSAMP,CDH20,NHSL1,PITPNC1,FGFR3,ATP13A4,NTM,HEPACAM,TRPS1,HIF3A |
1.101e-02 | -4.51 | Metabolism of fat-soluble vitamins | REACTOME pathways | R-HSA-6806667 | 53 | 2 | 10285 | 31 |
APOE,GPC5 |
1.101e-02 | -4.51 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
1.110e-02 | -4.50 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 3 | 19454 | 50 |
AHCYL2,FGFR3,CTNNA2 |
1.110e-02 | -4.50 | MYOD1 (myogenic differentiation 1) | protein interactions | 4654 | 180 | 3 | 19454 | 50 |
NFIA,RORA,TRPS1 |
1.115e-02 | -4.50 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 8 | 18204 | 49 |
PTPRZ1,APOE,CTNNA2,BMPR1B,GPM6A,NRXN1,TNIK,PREX2 |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
RYR3,GPC5,TRPS1,PAMR1 |
1.118e-02 | -4.49 | parietal_lobe | COSMIC cancer mutations | parietal_lobe | 55 | 2 | 16828 | 49 |
FGFR3,QKI |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 50 |
APOE |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.137e-02 | -4.48 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 49 |
ATP1A2,SLC4A4 |
1.141e-02 | -4.47 | Heparan sulfate/heparin (HS-GAG) metabolism | REACTOME pathways | R-HSA-1638091 | 54 | 2 | 10285 | 31 |
HPSE2,GPC5 |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.144e-02 | -4.47 | PARAOXONASE | prints domains | PR01785 | 3 | 1 | 5227 | 20 |
PON2 |
1.144e-02 | -4.47 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 20 |
RYR3 |
1.144e-02 | -4.47 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 20 |
GPM6A |
1.144e-02 | -4.47 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 20 |
PTGDS |
1.144e-02 | -4.47 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 20 |
RORA |
1.144e-02 | -4.47 | NLGN2 (neuroligin 2) | protein interactions | 57555 | 63 | 2 | 19454 | 50 |
NRXN1,CLU |
1.153e-02 | -4.46 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 49 |
SLC4A4,ATP1A2,APOE,SLC1A2,SLC1A3 |
1.153e-02 | -4.46 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 9 | 18204 | 49 |
ATP1A2,NFIA,RYR3,FGFR3,BMPR1B,SLC1A2,SLC1A3,SOX5,PTGDS |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.169e-02 | -4.45 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 38 |
MAML2 |
1.169e-02 | -4.45 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 38 |
GPM6A |
1.169e-02 | -4.45 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 38 |
AHCYL2 |
1.169e-02 | -4.45 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 38 |
AHCYL2 |
1.179e-02 | -4.44 | EVA1C (eva-1 homolog C) | protein interactions | 59271 | 64 | 2 | 19454 | 50 |
BMPR1B,PCDH9 |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
MAML2,DTNA |
1.184e-02 | -4.44 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 27 | 16828 | 49 |
COL5A3,NPAS3,SLC1A2,RORA,SOX5,HPSE2,RYR3,QKI,GPM6A,ZBTB20,GPC5,FBXL7,SLC4A4,PARD3B,CLU,PAMR1,APOE,NHSL1,CDH20,SLC1A3,PREX2,PITPNC1,FGFR3,NTM,MAML2,TRPS1,HIF3A |
1.190e-02 | -4.43 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 15 | 16828 | 49 |
SPARCL1,RYR3,TNIK,ZNRF3,FGFR3,PCDH9,TRPS1,COL5A3,CLU,SLC4A4,NKAIN3,PITPNC1,PTPRZ1,PREX2,NHSL1 |
1.190e-02 | -4.43 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 15 | 16828 | 49 |
SLC4A4,CLU,COL5A3,NHSL1,PTPRZ1,PREX2,PITPNC1,NKAIN3,FGFR3,PCDH9,ZNRF3,RYR3,TNIK,SPARCL1,TRPS1 |
1.196e-02 | -4.43 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 4 | 18204 | 49 |
RORA,APOE,SLC4A4,ZBTB20 |
1.205e-02 | -4.42 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 20 | 19454 | 50 |
TNIK,PITPNC1,DTNA,CST3,PON2,SLC4A4,QKI,MSI2,HEPACAM,NTM,CLU,PTPRZ1,GPM6A,AHCYL2,LSAMP,GLUL,ATP1A2,CTNNA2,SLC1A3,APOE |
1.211e-02 | -4.41 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.212e-02 | -4.41 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 12 | 16828 | 49 |
PCDH9,FGFR3,RORA,ZNRF3,HEPACAM,TRPS1,GPC5,MSI2,GPM6A,LSAMP,PREX2,PTPRZ1 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
RYR3,GPC5,GPM6A,TRPS1,PAMR1 |
1.224e-02 | -4.40 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 2 | 10285 | 31 |
RYR3,ATP1A2 |
1.230e-02 | -4.40 | KLF5 (KLF transcription factor 5) | protein interactions | 688 | 187 | 3 | 19454 | 50 |
NFIA,CLU,TRPS1 |
1.237e-02 | -4.39 | lipid homeostasis | biological process | GO:0055088 | 179 | 3 | 18204 | 49 |
ZBTB20,RORA,APOE |
1.239e-02 | -4.39 | adherens junction | cellular component | GO:0005912 | 188 | 3 | 19108 | 49 |
CDH20,CTNNA2,PARD3B |
1.248e-02 | -4.38 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
1.249e-02 | -4.38 | regulation of nitric oxide biosynthetic process | biological process | GO:0045428 | 63 | 2 | 18204 | 49 |
CLU,APOE |
1.249e-02 | -4.38 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 49 |
TNIK,ATP1A2,PREX2,FGFR3 |
1.250e-02 | -4.38 | ORM1 (orosomucoid 1) | protein interactions | 5004 | 66 | 2 | 19454 | 50 |
PTGDS,CLU |
1.250e-02 | -4.38 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 2 | 19454 | 50 |
APOE,CLU |
1.250e-02 | -4.38 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 50 |
NFIA,MAML2 |
1.254e-02 | -4.38 | Erythroid Transcription Factor GATA-1, subunit A | gene3d domains | 3.30.50.10 | 56 | 2 | 14470 | 44 |
RORA,TRPS1 |
1.275e-02 | -4.36 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
1.276e-02 | -4.36 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 49 |
CLU |
1.279e-02 | -4.36 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 50 |
AHCYL2 |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 50 |
NRXN1 |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.283e-02 | -4.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 24 | 18094 | 47 |
GLIS3,ATP1A2,ZNRF3,BMPR1B,PON2,SLC1A3,FGFR3,TNIK,ZBTB20,ATP13A4,DTNA,GLUL,RORA,RYR3,SLC1A2,APOE,SPARCL1,NRXN1,PITPNC1,TRPS1,CPE,PCDH9,PAMR1,PTGDS |
1.287e-02 | -4.35 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 2 | 18204 | 49 |
PREX2,CTNNA2 |
1.292e-02 | -4.35 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 47 |
NRXN1 |
1.292e-02 | -4.35 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 47 |
FGFR3 |
1.292e-02 | -4.35 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 47 |
BMPR1B |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
PTGDS,ZNRF3,PCDH9,MAML2,GLIS3,NRXN1,CPE,APOE,PARD3B,SLC1A3,PREX2,QKI,RORA,HPSE2,RYR3,TNIK,NFIA,GPM6A,ZBTB20,GPC5,BMPR1B,GLUL,NKAIN3,NPAS3,SLC1A2,PTPRZ1,ATP13A4,FGFR3,NTM,HEPACAM,TRPS1,HIF3A,PAMR1,LSAMP,AHCYL2,SLC4A4,ATP1A2,CLU,PITPNC1,NHSL1,CDH20,SPARCL1,SOX5,FBXL7,CST3,MSI2,COL5A3,PON2 |
1.309e-02 | -4.34 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 31 |
ATP1A2,ATP13A4 |
1.310e-02 | -4.34 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 49 |
PCDH9,SLC4A4,ATP13A4,RYR3,LSAMP |
1.310e-02 | -4.34 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 49 |
SLC4A4,PCDH9,ATP13A4,RYR3,LSAMP |
1.312e-02 | -4.33 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 49 |
SLC4A4,RORA,ZBTB20 |
1.317e-02 | -4.33 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 7 | 16828 | 49 |
PCDH9,FGFR3,PAMR1,GLIS3,PREX2,NFIA,HIF3A |
1.325e-02 | -4.32 | regulation of nitric oxide metabolic process | biological process | GO:0080164 | 65 | 2 | 18204 | 49 |
APOE,CLU |
1.328e-02 | -4.32 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 10 | 18204 | 49 |
CLU,ATP1A2,APOE,ZBTB20,NRXN1,BMPR1B,RORA,QKI,PTPRZ1,SOX5 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.339e-02 | -4.31 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 49 |
ATP1A2 |
1.339e-02 | -4.31 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 49 |
NRXN1 |
1.339e-02 | -4.31 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 49 |
CLU |
1.339e-02 | -4.31 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 49 |
BMPR1B |
1.339e-02 | -4.31 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 49 |
APOE |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | BBP-like | interpro domains | IPR045071 | 5 | 1 | 18521 | 50 |
QKI |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.349e-02 | -4.31 | collagen binding | molecular function | GO:0005518 | 68 | 2 | 18094 | 47 |
COL5A3,SPARCL1 |
1.352e-02 | -4.30 | Arachidonic acid metabolism | REACTOME pathways | R-HSA-2142753 | 59 | 2 | 10285 | 31 |
PON2,PTGDS |
1.356e-02 | -4.30 | arm | COSMIC cancer mutations | arm | 1331 | 9 | 16828 | 49 |
NPAS3,ZBTB20,TRPS1,SLC4A4,FGFR3,ATP1A2,NTM,PARD3B,COL5A3 |
1.364e-02 | -4.29 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.365e-02 | -4.29 | blood vessel development | biological process | GO:0001568 | 530 | 5 | 18204 | 49 |
GLUL,HIF3A,QKI,RORA,APOE |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
HIF3A,TRPS1,HEPACAM,NTM,FGFR3,ATP13A4,CDH20,NHSL1,LSAMP,PAMR1,CLU,ATP1A2,SLC4A4,AHCYL2,FBXL7,MSI2,CST3,DTNA,SPARCL1,SOX5,PON2,COL5A3,NRXN1,GLIS3,MAML2,PCDH9,PTGDS,ZNRF3,SLC1A3,PREX2,APOE,CPE,PARD3B,NFIA,GPC5,ZBTB20,GPM6A,QKI,TNIK,RYR3,HPSE2,RORA,NKAIN3,PTPRZ1,SLC1A2,NPAS3,BMPR1B,GLUL |
1.368e-02 | -4.29 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 38 |
HEPACAM,LSAMP,NTM,FGFR3 |
1.372e-02 | -4.29 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 42 |
NFIA |
1.372e-02 | -4.29 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 42 |
NFIA |
1.397e-02 | -4.27 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 50 |
SPARCL1 |
1.397e-02 | -4.27 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 50 |
PCDH9 |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.399e-02 | -4.27 | PCDH20 (protocadherin 20) | protein interactions | 64881 | 70 | 2 | 19454 | 50 |
PON2,CTNNA2 |
1.400e-02 | -4.27 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 49 |
GPC5,ZBTB20,GPM6A,HIF3A,RYR3,HPSE2,SOX5,PCDH9,FGFR3,PTPRZ1,CDH20,NPAS3,BMPR1B,APOE,COL5A3 |
1.403e-02 | -4.27 | cell projection organization | biological process | GO:0030030 | 1200 | 8 | 18204 | 49 |
CTNNA2,BMPR1B,PTPRZ1,APOE,PREX2,GPM6A,NRXN1,TNIK |
1.404e-02 | -4.27 | cholesterol transport | biological process | GO:0030301 | 67 | 2 | 18204 | 49 |
APOE,CLU |
1.405e-02 | -4.27 | monoatomic ion transport | biological process | GO:0006811 | 964 | 7 | 18204 | 49 |
ATP13A4,RYR3,SLC4A4,ATP1A2,GPM6A,SLC1A3,SLC1A2 |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
ZNRF3,PTGDS,PCDH9,MAML2,GLIS3,NRXN1,CPE,APOE,PARD3B,PREX2,SLC1A3,QKI,RORA,HPSE2,TNIK,RYR3,NFIA,GPM6A,ZBTB20,GPC5,BMPR1B,GLUL,NKAIN3,NPAS3,SLC1A2,PTPRZ1,ATP13A4,FGFR3,NTM,TRPS1,HEPACAM,HIF3A,PAMR1,LSAMP,AHCYL2,SLC4A4,CLU,ATP1A2,PITPNC1,NHSL1,CDH20,SPARCL1,SOX5,FBXL7,DTNA,CST3,COL5A3,PON2 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
SLC1A3,PREX2,PARD3B,APOE,CPE,NRXN1,GLIS3,MAML2,PCDH9,PTGDS,ZNRF3,PTPRZ1,SLC1A2,NPAS3,NKAIN3,GLUL,BMPR1B,GPC5,ZBTB20,GPM6A,NFIA,RYR3,TNIK,HPSE2,RORA,QKI,CDH20,NHSL1,PITPNC1,CLU,ATP1A2,AHCYL2,SLC4A4,LSAMP,PAMR1,HIF3A,TRPS1,HEPACAM,NTM,FGFR3,ATP13A4,PON2,COL5A3,DTNA,CST3,FBXL7,SOX5,SPARCL1 |
1.433e-02 | -4.25 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.437e-02 | -4.24 | UNKL (unk like zinc finger) | protein interactions | 64718 | 71 | 2 | 19454 | 50 |
AHCYL2,QKI |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.467e-02 | -4.22 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 5 | 18094 | 47 |
CDH20,NRXN1,CTNNA2,PTPRZ1,CPE |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
PARD3B,BMPR1B |
1.480e-02 | -4.21 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 50 |
PAMR1,NRXN1 |
1.488e-02 | -4.21 | human chr19q13.32 | chromosome location | human chr19q13.32 | 97 | 2 | 26134 | 50 |
APOE,HIF3A |
1.492e-02 | -4.21 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 3 | 19454 | 50 |
DTNA,ATP1A2,RYR3 |
1.511e-02 | -4.19 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 44 |
APOE |
1.512e-02 | -4.19 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
1.520e-02 | -4.19 | ORF3a (ORF3a protein) | protein interactions | 43740569 | 789 | 6 | 19454 | 50 |
BMPR1B,ZNRF3,CLU,PARD3B,PCDH9,SLC4A4 |
1.521e-02 | -4.19 | plasma membrane region | cellular component | GO:0098590 | 1278 | 8 | 19108 | 49 |
ATP1A2,SLC4A4,PARD3B,TNIK,SLC1A3,NRXN1,GPM6A,SLC1A2 |
1.522e-02 | -4.19 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 20 |
CTNNA2 |
1.529e-02 | -4.18 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 49 |
APOE |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | TAT (tyrosine aminotransferase) | protein interactions | 6898 | 6 | 1 | 19454 | 50 |
GLUL |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | PBP2 (Pbp2p) | protein interactions | 852533 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | CYP39A1 (cytochrome P450 family 39 subfamily A member 1) | protein interactions | 51302 | 6 | 1 | 19454 | 50 |
GLUL |
1.532e-02 | -4.18 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DAZ4 (deleted in azoospermia 4) | protein interactions | 57135 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 50 |
NRXN1 |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.535e-02 | -4.18 | cell-cell adhesion | biological process | GO:0098609 | 546 | 5 | 18204 | 49 |
CDH20,NRXN1,PCDH9,CTNNA2,SPARCL1 |
1.547e-02 | -4.17 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 2 |
PTGDS |
1.547e-02 | -4.17 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 2 |
PTGDS |
1.547e-02 | -4.17 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 49 |
ATP1A2,PCDH9 |
1.549e-02 | -4.17 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 47 |
SLC4A4 |
1.549e-02 | -4.17 | arylesterase activity | molecular function | GO:0004064 | 6 | 1 | 18094 | 47 |
PON2 |
1.549e-02 | -4.17 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 47 |
APOE |
1.549e-02 | -4.17 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 47 |
RYR3 |
1.549e-02 | -4.17 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 47 |
ATP1A2 |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
NRXN1,DTNA,PARD3B |
1.552e-02 | -4.17 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 50 |
TRPS1,SOX5,NFIA |
1.554e-02 | -4.16 | CACNA2D1 (calcium voltage-gated channel auxiliary subunit alpha2delta 1) | protein interactions | 781 | 74 | 2 | 19454 | 50 |
GPM6A,PON2 |
1.579e-02 | -4.15 | vasculature development | biological process | GO:0001944 | 550 | 5 | 18204 | 49 |
RORA,APOE,QKI,HIF3A,GLUL |
1.597e-02 | -4.14 | locomotory behavior | biological process | GO:0007626 | 197 | 3 | 18204 | 49 |
PREX2,APOE,ATP1A2 |
1.597e-02 | -4.14 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 20 |
SLC1A3,ATP1A2 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
NKAIN3,PTPRZ1,NPAS3,SLC1A2,BMPR1B,GLUL,NFIA,ZBTB20,GPC5,GPM6A,QKI,HPSE2,TNIK,RYR3,RORA,SLC1A3,PREX2,CPE,APOE,PARD3B,NRXN1,GLIS3,MAML2,PTGDS,ZNRF3,PCDH9,PON2,COL5A3,FBXL7,MSI2,DTNA,CST3,SPARCL1,SOX5,NHSL1,CDH20,LSAMP,PAMR1,CLU,ATP1A2,SLC4A4,AHCYL2,HIF3A,TRPS1,HEPACAM,NTM,ATP13A4,FGFR3 |
1.604e-02 | -4.13 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 49 |
CST3 |
1.604e-02 | -4.13 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 49 |
SOX5 |
1.604e-02 | -4.13 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 49 |
SLC1A3 |
1.604e-02 | -4.13 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 49 |
CLU |
1.604e-02 | -4.13 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 49 |
BMPR1B |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 50 |
GLIS3 |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.616e-02 | -4.13 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 49 |
GPC5,RYR3,PCDH9 |
1.618e-02 | -4.12 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 14 | 16828 | 49 |
TRPS1,NRXN1,ATP13A4,PCDH9,SOX5,MAML2,HPSE2,RYR3,CDH20,PREX2,PTPRZ1,SLC1A3,LSAMP,ATP1A2 |
1.632e-02 | -4.12 | monoatomic cation transport | biological process | GO:0006812 | 766 | 6 | 18204 | 49 |
GPM6A,SLC1A3,RYR3,ATP13A4,SLC4A4,ATP1A2 |
1.633e-02 | -4.11 | RYK (receptor like tyrosine kinase) | protein interactions | 6259 | 208 | 3 | 19454 | 50 |
CTNNA2,CLU,PCDH9 |
1.635e-02 | -4.11 | MIR200A (microRNA 200a) | protein interactions | 406983 | 76 | 2 | 19454 | 50 |
MSI2,QKI |
1.652e-02 | -4.10 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 49 |
CPE,SLC1A2 |
1.673e-02 | -4.09 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 49 |
NRXN1,PTPRZ1,BMPR1B,CTNNA2 |
1.674e-02 | -4.09 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 50 |
NRXN1 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.695e-02 | -4.08 | sterol transport | biological process | GO:0015918 | 74 | 2 | 18204 | 49 |
APOE,CLU |
1.695e-02 | -4.08 | positive regulation of gliogenesis | biological process | GO:0014015 | 74 | 2 | 18204 | 49 |
PTPRZ1,QKI |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.706e-02 | -4.07 | intracellular calcium ion homeostasis | biological process | GO:0006874 | 202 | 3 | 18204 | 49 |
ATP13A4,RYR3,APOE |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.715e-02 | -4.07 | extremity | COSMIC cancer mutations | extremity | 1876 | 11 | 16828 | 49 |
PREX2,PTPRZ1,CDH20,PITPNC1,COL5A3,FBXL7,RYR3,HPSE2,PCDH9,FGFR3,ATP13A4 |
1.717e-02 | -4.06 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 50 |
CLU,APOE |
1.717e-02 | -4.06 | MIR34C (microRNA 34c) | protein interactions | 407042 | 78 | 2 | 19454 | 50 |
QKI,MSI2 |
1.717e-02 | -4.06 | IFIT3 (interferon induced protein with tetratricopeptide repeats 3) | protein interactions | 3437 | 78 | 2 | 19454 | 50 |
ATP1A2,APOE |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
MSI2,SOX5 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.738e-02 | -4.05 | regulation of behavior | biological process | GO:0050795 | 75 | 2 | 18204 | 49 |
PTGDS,APOE |
1.738e-02 | -4.05 | amino acid biosynthetic process | biological process | GO:0008652 | 75 | 2 | 18204 | 49 |
SLC1A3,GLUL |
1.751e-02 | -4.05 | face | COSMIC cancer mutations | face | 2139 | 12 | 16828 | 49 |
ZNRF3,RORA,PCDH9,FGFR3,TRPS1,HEPACAM,MSI2,GPC5,GPM6A,LSAMP,PTPRZ1,PREX2 |
1.759e-02 | -4.04 | NUCB2 (nucleobindin 2) | protein interactions | 4925 | 79 | 2 | 19454 | 50 |
CLU,GLUL |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.786e-02 | -4.03 | Pum2 (pumilio RNA-binding family member 2) | protein interactions | 80913 | 7 | 1 | 19454 | 50 |
QKI |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 50 |
AHCYL2 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.801e-02 | -4.02 | MAP2 (microtubule associated protein 2) | protein interactions | 4133 | 80 | 2 | 19454 | 50 |
APOE,GPM6A |
1.804e-02 | -4.01 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 47 |
PITPNC1 |
1.804e-02 | -4.01 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.804e-02 | -4.01 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.811e-02 | -4.01 | Glutamine synthetase/guanido kinase, catalytic domain | gene3d domains | 3.30.590.10 | 6 | 1 | 14470 | 44 |
GLUL |
1.811e-02 | -4.01 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 44 |
RYR3 |
1.827e-02 | -4.00 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 49 |
BMPR1B,NFIA |
1.827e-02 | -4.00 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 49 |
ATP1A2,NRXN1 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.869e-02 | -3.98 | regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905868 | 7 | 1 | 18204 | 49 |
QKI |
1.869e-02 | -3.98 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 49 |
CTNNA2 |
1.869e-02 | -3.98 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 49 |
NFIA |
1.869e-02 | -3.98 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 49 |
ZNRF3 |
1.869e-02 | -3.98 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 49 |
PTPRZ1 |
1.869e-02 | -3.98 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 49 |
PTGDS |
1.869e-02 | -3.98 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 49 |
MAML2 |
1.869e-02 | -3.98 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 49 |
RYR3 |
1.869e-02 | -3.98 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 49 |
NRXN1 |
1.869e-02 | -3.98 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 49 |
CLU |
1.869e-02 | -3.98 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 49 |
AHCYL2 |
1.872e-02 | -3.98 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
1.872e-02 | -3.98 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.878e-02 | -3.97 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 47 |
BMPR1B,FGFR3 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.899e-02 | -3.96 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 20 |
SLC4A4 |
1.899e-02 | -3.96 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 20 |
PITPNC1 |
1.917e-02 | -3.95 | regulation of glial cell differentiation | biological process | GO:0045685 | 79 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
1.922e-02 | -3.95 | prostate | COSMIC cancer mutations | prostate | 13883 | 46 | 16828 | 49 |
HEPACAM,TRPS1,HIF3A,FGFR3,ATP13A4,NTM,CDH20,NHSL1,PITPNC1,AHCYL2,SLC4A4,CLU,ATP1A2,PAMR1,LSAMP,DTNA,MSI2,FBXL7,SOX5,SPARCL1,PON2,COL5A3,GLIS3,NRXN1,PCDH9,ZNRF3,MAML2,SLC1A3,PREX2,PARD3B,APOE,CPE,GPM6A,GPC5,ZBTB20,NFIA,RORA,HPSE2,RYR3,TNIK,QKI,SLC1A2,NPAS3,PTPRZ1,NKAIN3,BMPR1B |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.930e-02 | -3.95 | TM2D3 (TM2 domain containing 3) | protein interactions | 80213 | 83 | 2 | 19454 | 50 |
FGFR3,PON2 |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
GPM6A,NRXN1 |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
FGFR3,GPM6A |
1.951e-02 | -3.94 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 50 |
SPARCL1 |
1.951e-02 | -3.94 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 50 |
BMPR1B |
1.989e-02 | -3.92 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 4 | 10285 | 31 |
GLUL,SLC1A2,NRXN1,SLC1A3 |
2.008e-02 | -3.91 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 3 | 19454 | 50 |
NFIA,SOX5,TRPS1 |
2.009e-02 | -3.91 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 49 |
ATP1A2,PREX2 |
2.009e-02 | -3.91 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 2 | 18204 | 49 |
CLU,APOE |
2.018e-02 | -3.90 | CCND3 (cyclin D3) | protein interactions | 896 | 85 | 2 | 19454 | 50 |
QKI,CLU |
2.020e-02 | -3.90 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 8 | 19454 | 50 |
TRPS1,LSAMP,QKI,MSI2,NFIA,GLIS3,CLU,SOX5 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.034e-02 | -3.90 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 49 |
CLU |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.038e-02 | -3.89 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 50 |
PTGDS |
2.038e-02 | -3.89 | DEPP1 (DEPP autophagy regulator 1) | protein interactions | 11067 | 8 | 1 | 19454 | 50 |
QKI |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.051e-02 | -3.89 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 42 |
GPC5 |
2.059e-02 | -3.88 | positive regulation of cellular catabolic process | biological process | GO:0031331 | 217 | 3 | 18204 | 49 |
SLC4A4,APOE,ZBTB20 |
2.060e-02 | -3.88 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 47 |
BMPR1B |
2.060e-02 | -3.88 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.060e-02 | -3.88 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.060e-02 | -3.88 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 47 |
SLC1A3 |
2.063e-02 | -3.88 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 50 |
FGFR3,HIF3A |
2.084e-02 | -3.87 | dendrite | cellular component | GO:0030425 | 620 | 5 | 19108 | 49 |
GPM6A,APOE,CLU,BMPR1B,ATP1A2 |
2.091e-02 | -3.87 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 31 |
FGFR3 |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
TRPS1,SLC1A3 |
2.108e-02 | -3.86 | MIR141 (microRNA 141) | protein interactions | 406933 | 87 | 2 | 19454 | 50 |
MSI2,QKI |
2.108e-02 | -3.86 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.110e-02 | -3.86 | dendritic tree | cellular component | GO:0097447 | 622 | 5 | 19108 | 49 |
CLU,APOE,GPM6A,ATP1A2,BMPR1B |
2.123e-02 | -3.85 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
GLIS3,NRXN1,PCDH9,PTGDS,ZNRF3,MAML2,PREX2,SLC1A3,PARD3B,APOE,CPE,GPM6A,GPC5,ZBTB20,NFIA,RORA,TNIK,HPSE2,RYR3,QKI,SLC1A2,NPAS3,PTPRZ1,NKAIN3,GLUL,BMPR1B,TRPS1,HEPACAM,HIF3A,FGFR3,ATP13A4,CDH20,NHSL1,PITPNC1,SLC4A4,AHCYL2,ATP1A2,CLU,PAMR1,LSAMP,DTNA,MSI2,FBXL7,SOX5,SPARCL1,COL5A3 |
2.123e-02 | -3.85 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
CPE,APOE,PARD3B,PREX2,SLC1A3,MAML2,PTGDS,ZNRF3,PCDH9,NRXN1,GLIS3,BMPR1B,GLUL,NKAIN3,PTPRZ1,NPAS3,SLC1A2,QKI,RYR3,HPSE2,TNIK,RORA,NFIA,ZBTB20,GPC5,GPM6A,LSAMP,PAMR1,CLU,ATP1A2,SLC4A4,AHCYL2,PITPNC1,NHSL1,CDH20,ATP13A4,FGFR3,HIF3A,HEPACAM,TRPS1,COL5A3,SPARCL1,SOX5,FBXL7,MSI2,DTNA |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.125e-02 | -3.85 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 12 | 16828 | 49 |
FGFR3,SOX5,TNIK,DTNA,NFIA,TRPS1,SLC4A4,PARD3B,ATP1A2,BMPR1B,PTPRZ1,PREX2 |
2.126e-02 | -3.85 | femur | COSMIC cancer mutations | femur | 1197 | 8 | 16828 | 49 |
PON2,GPC5,PTPRZ1,SLC4A4,PCDH9,GLUL,HPSE2,RYR3 |
2.127e-02 | -3.85 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 50 |
RYR3,NRXN1,COL5A3 |
2.134e-02 | -3.85 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 49 |
CPE |
2.134e-02 | -3.85 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 49 |
CTNNA2 |
2.134e-02 | -3.85 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 49 |
SLC1A3 |
2.134e-02 | -3.85 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 49 |
PTGDS |
2.134e-02 | -3.85 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 49 |
ATP1A2 |
2.134e-02 | -3.85 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | glutamate catabolic process | biological process | GO:0006538 | 8 | 1 | 18204 | 49 |
GLUL |
2.134e-02 | -3.85 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 49 |
ATP1A2,SLC1A3,NRXN1 |
2.140e-02 | -3.84 | Gln_synth/guanido_kin_cat_dom | interpro domains | IPR014746 | 8 | 1 | 18521 | 50 |
GLUL |
2.144e-02 | -3.84 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 23 |
SLC4A4,ATP1A2 |
2.144e-02 | -3.84 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 23 |
SLC4A4,ATP1A2 |
2.151e-02 | -3.84 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.151e-02 | -3.84 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 49 |
NKAIN3,ATP1A2 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
BMPR1B,TNIK |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
FGFR3,HEPACAM,NTM,LSAMP |
2.175e-02 | -3.83 | CTSB (cathepsin B) | protein interactions | 1508 | 232 | 3 | 19454 | 50 |
CST3,APOE,MSI2 |
2.199e-02 | -3.82 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 2 | 18204 | 49 |
PTPRZ1,CLU |
2.199e-02 | -3.82 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 50 |
AHCYL2,DTNA |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.201e-02 | -3.82 | organic anion transport | biological process | GO:0015711 | 398 | 4 | 18204 | 49 |
SLC1A3,SLC4A4,APOE,SLC1A2 |
2.221e-02 | -3.81 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 8 | 18094 | 47 |
HIF3A,GLIS3,NFIA,NPAS3,TRPS1,SOX5,ZBTB20,RORA |
2.224e-02 | -3.81 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 50 |
NFIA,DTNA,SOX5 |
2.243e-02 | -3.80 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 8 | 16828 | 49 |
LSAMP,SOX5,TNIK,HPSE2,RORA,PCDH9,NKAIN3,GPC5 |
2.262e-02 | -3.79 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 7 | 16828 | 49 |
NKAIN3,GPC5,LSAMP,RORA,PCDH9,SOX5,HPSE2 |
2.272e-02 | -3.78 | human chr6q26 | chromosome location | human chr6q26 | 12 | 1 | 26134 | 50 |
QKI |
2.274e-02 | -3.78 | CTSL (cathepsin L) | protein interactions | 1514 | 236 | 3 | 19454 | 50 |
CLU,PON2,CST3 |
2.275e-02 | -3.78 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 20 |
BMPR1B |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | Ywhag (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide) | protein interactions | 22628 | 9 | 1 | 19454 | 50 |
QKI |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
NTM,GPM6A |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | 8 | 1 | 16828 | 49 |
QKI |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.320e-02 | -3.76 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 4 |
FGFR3 |
2.323e-02 | -3.76 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 47 |
RORA,PTGDS,APOE,ATP1A2,PITPNC1,PARD3B |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
SPARCL1,GLUL,CLU |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
TNIK,FGFR3 |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.339e-02 | -3.76 | RLN1 (relaxin 1) | protein interactions | 6013 | 92 | 2 | 19454 | 50 |
CPE,PON2 |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.341e-02 | -3.75 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 49 |
BMPR1B,FGFR3,SOX5 |
2.351e-02 | -3.75 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 7 | 18094 | 47 |
SLC1A3,RYR3,ATP1A2,GPM6A,ATP13A4,SLC4A4,SLC1A2 |
2.375e-02 | -3.74 | ATP6V1A (ATPase H+ transporting V1 subunit A) | protein interactions | 523 | 240 | 3 | 19454 | 50 |
PON2,ATP1A2,APOE |
2.387e-02 | -3.74 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 31 |
GPC5 |
2.387e-02 | -3.74 | MIR19B2 (microRNA 19b-2) | protein interactions | 406981 | 93 | 2 | 19454 | 50 |
QKI,MSI2 |
2.387e-02 | -3.74 | RBM23 (RNA binding motif protein 23) | protein interactions | 55147 | 93 | 2 | 19454 | 50 |
QKI,AHCYL2 |
2.387e-02 | -3.74 | DMRTB1 (DMRT like family B with proline rich C-terminal 1) | protein interactions | 63948 | 93 | 2 | 19454 | 50 |
QKI,MSI2 |
2.387e-02 | -3.74 | TEX11 (testis expressed 11) | protein interactions | 56159 | 93 | 2 | 19454 | 50 |
QKI,SOX5 |
2.388e-02 | -3.73 | hand | COSMIC cancer mutations | hand | 566 | 5 | 16828 | 49 |
COL5A3,HIF3A,FGFR3,SLC4A4,PREX2 |
2.388e-02 | -3.73 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 42 |
BMPR1B |
2.395e-02 | -3.73 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 49 |
APOE,ZBTB20 |
2.397e-02 | -3.73 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 49 |
ATP13A4 |
2.397e-02 | -3.73 | regulation of protein localization to nucleolus | biological process | GO:1904749 | 9 | 1 | 18204 | 49 |
GLUL |
2.397e-02 | -3.73 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 49 |
PTGDS |
2.397e-02 | -3.73 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 49 |
NRXN1 |
2.397e-02 | -3.73 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 49 |
ATP1A2 |
2.397e-02 | -3.73 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 49 |
CLU |
2.397e-02 | -3.73 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 49 |
RYR3 |
2.397e-02 | -3.73 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 49 |
CLU |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.411e-02 | -3.73 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 49 |
APOE,ATP1A2,FGFR3,RYR3,TNIK,PREX2 |
2.422e-02 | -3.72 | calcium ion homeostasis | biological process | GO:0055074 | 231 | 3 | 18204 | 49 |
APOE,RYR3,ATP13A4 |
2.433e-02 | -3.72 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 20 |
SOX5,FGFR3 |
2.435e-02 | -3.72 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.435e-02 | -3.72 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.446e-02 | -3.71 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
2.446e-02 | -3.71 | lipoprotein biosynthetic process | biological process | GO:0042158 | 90 | 2 | 18204 | 49 |
GLUL,APOE |
2.448e-02 | -3.71 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 31 |
RYR3,ATP1A2,ATP13A4 |
2.453e-02 | -3.71 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 29 | 16828 | 49 |
SLC1A3,PREX2,PARD3B,ATP1A2,SLC4A4,PAMR1,NRXN1,GLIS3,HIF3A,TRPS1,MAML2,PTGDS,ATP13A4,FGFR3,PTPRZ1,NPAS3,PON2,NKAIN3,GLUL,COL5A3,ZBTB20,DTNA,CST3,SOX5,TNIK,RYR3,RORA,SPARCL1,QKI |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.476e-02 | -3.70 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 5 | 18204 | 49 |
RYR3,SLC1A3,GPM6A,ATP1A2,SLC4A4 |
2.487e-02 | -3.69 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 6 | 18204 | 49 |
ATP1A2,RYR3,RORA,SLC1A2,PTGDS,SLC1A3 |
2.496e-02 | -3.69 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 8 | 18094 | 47 |
TRPS1,SOX5,NPAS3,NFIA,HIF3A,GLIS3,RORA,ZBTB20 |
2.496e-02 | -3.69 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 49 |
NFIA,BMPR1B |
2.496e-02 | -3.69 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
2.496e-02 | -3.69 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 49 |
BMPR1B,NFIA |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 50 |
BMPR1B |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.537e-02 | -3.67 | positive regulation of catabolic process | biological process | GO:0009896 | 622 | 5 | 18204 | 49 |
ZBTB20,QKI,APOE,CLU,SLC4A4 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | ALKAL2 (ALK and LTK ligand 2) | protein interactions | 285016 | 10 | 1 | 19454 | 50 |
PON2 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Hsp90aa1 (heat shock protein 90, alpha (cytosolic), class A member 1) | protein interactions | 15519 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | Mrpl13 (mitochondrial ribosomal protein L13) | protein interactions | 68537 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.568e-02 | -3.66 | spindle | COSMIC cancer mutations | spindle | 386 | 4 | 16828 | 49 |
PCDH9,FGFR3,PREX2,CPE |
2.568e-02 | -3.66 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 47 |
PITPNC1 |
2.568e-02 | -3.66 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 47 |
ATP13A4 |
2.580e-02 | -3.66 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
SOX5,TNIK,NFIA |
2.590e-02 | -3.65 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 9 | 16828 | 49 |
GPC5,PTPRZ1,PREX2,DTNA,NPAS3,RYR3,PARD3B,FGFR3,PCDH9 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.616e-02 | -3.64 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 49 |
RYR3,DTNA,ATP1A2 |
2.618e-02 | -3.64 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 49 |
NRXN1,PTPRZ1,CTNNA2,BMPR1B |
2.631e-02 | -3.64 | MED27 (mediator complex subunit 27) | protein interactions | 9442 | 98 | 2 | 19454 | 50 |
SOX5,QKI |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
LSAMP,GPM6A |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.660e-02 | -3.63 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 49 |
RYR3 |
2.660e-02 | -3.63 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 49 |
SOX5 |
2.660e-02 | -3.63 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | action potential propagation | biological process | GO:0098870 | 10 | 1 | 18204 | 49 |
ATP1A2 |
2.660e-02 | -3.63 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 49 |
PARD3B |
2.660e-02 | -3.63 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 1 | 18204 | 49 |
ATP1A2 |
2.660e-02 | -3.63 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.662e-02 | -3.63 | metal ion transport | biological process | GO:0030001 | 630 | 5 | 18204 | 49 |
ATP1A2,SLC4A4,SLC1A3,RYR3,GPM6A |
2.666e-02 | -3.62 | TGFBR1 (transforming growth factor beta receptor 1) | protein interactions | 7046 | 251 | 3 | 19454 | 50 |
PREX2,BMPR1B,CLU |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.680e-02 | -3.62 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 50 |
TNIK,PCDH9 |
2.680e-02 | -3.62 | TPP1 (tripeptidyl peptidase 1) | protein interactions | 1200 | 99 | 2 | 19454 | 50 |
APOE,PON2 |
2.680e-02 | -3.62 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 50 |
SOX5,TRPS1 |
2.681e-02 | -3.62 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 31 |
CLU |
2.681e-02 | -3.62 | Synthesis of 5-eicosatetraenoic acids | REACTOME pathways | R-HSA-2142688 | 9 | 1 | 10285 | 31 |
PON2 |
2.693e-02 | -3.61 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
2.697e-02 | -3.61 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 3 | 10285 | 31 |
SLC1A3,GLUL,SLC1A2 |
2.706e-02 | -3.61 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 38 |
BMPR1B |
2.725e-02 | -3.60 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 42 |
TRPS1 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
GPM6A,ATP1A2 |
2.731e-02 | -3.60 | EDEM2 (ER degradation enhancing alpha-mannosidase like protein 2) | protein interactions | 55741 | 100 | 2 | 19454 | 50 |
CLU,HPSE2 |
2.775e-02 | -3.58 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 50 |
RYR3 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
NHSL1,NFIA,TRPS1 |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.782e-02 | -3.58 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 50 |
NRXN1 |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | IL7 (interleukin 7) | protein interactions | 3574 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 50 |
PTGDS |
2.792e-02 | -3.58 | DAZ1 (deleted in azoospermia 1) | protein interactions | 1617 | 11 | 1 | 19454 | 50 |
QKI |
2.810e-02 | -3.57 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.817e-02 | -3.57 | amide binding | molecular function | GO:0033218 | 254 | 3 | 18094 | 47 |
CST3,APOE,CLU |
2.821e-02 | -3.57 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 47 |
SLC1A2 |
2.821e-02 | -3.57 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 47 |
NRXN1 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | MIR7-1 (microRNA 7-1) | protein interactions | 407043 | 102 | 2 | 19454 | 50 |
MSI2,QKI |
2.849e-02 | -3.56 | protein binding | molecular function | GO:0005515 | 13983 | 42 | 18094 | 47 |
PTPRZ1,DTNA,NPAS3,HPSE2,GLUL,CTNNA2,RYR3,RORA,CDH20,CLU,SPARCL1,NRXN1,NTM,SLC1A2,APOE,TRPS1,MAML2,PITPNC1,PARD3B,CST3,COL5A3,CPE,FBXL7,PTGDS,QKI,GPC5,SOX5,NFIA,HIF3A,GLIS3,ZNRF3,ATP1A2,SLC4A4,PON2,BMPR1B,SLC1A3,FGFR3,LSAMP,TNIK,AHCYL2,MSI2,GPM6A |
2.855e-02 | -3.56 | Heparan sulfate degradation | KEGG pathways | hsa_M00078 | 9 | 1 | 7161 | 23 |
HPSE2 |
2.855e-02 | -3.56 | Heparan sulfate degradation | KEGG pathways | M00078 | 9 | 1 | 7161 | 23 |
HPSE2 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | chiasm | COSMIC cancer mutations | chiasm | 10 | 1 | 16828 | 49 |
QKI |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
BMPR1B,GPM6A |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTM,LSAMP,FGFR3,HEPACAM |
2.917e-02 | -3.53 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
2.917e-02 | -3.53 | phospholipid transport | biological process | GO:0015914 | 99 | 2 | 18204 | 49 |
APOE,PITPNC1 |
2.922e-02 | -3.53 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 49 |
BMPR1B |
2.922e-02 | -3.53 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | intracellular mRNA localization | biological process | GO:0008298 | 11 | 1 | 18204 | 49 |
QKI |
2.922e-02 | -3.53 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 49 |
RYR3 |
2.922e-02 | -3.53 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 49 |
ATP13A4 |
2.931e-02 | -3.53 | Fib_collagen_C | interpro domains | IPR000885 | 11 | 1 | 18521 | 50 |
COL5A3 |
2.932e-02 | -3.53 | peptide binding | molecular function | GO:0042277 | 258 | 3 | 18094 | 47 |
APOE,CLU,CST3 |
2.936e-02 | -3.53 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 2 | 19454 | 50 |
SPARCL1,CLU |
2.975e-02 | -3.51 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 31 |
FGFR3 |
2.976e-02 | -3.51 | Phase I biotransformations, non P450 | WikiPathways | WP136 | 8 | 1 | 5310 | 20 |
PON2 |
2.988e-02 | -3.51 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 50 |
TNIK,TRPS1 |
2.988e-02 | -3.51 | ABCA2 (ATP binding cassette subfamily A member 2) | protein interactions | 20 | 105 | 2 | 19454 | 50 |
PON2,FGFR3 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.022e-02 | -3.50 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 20 |
TRPS1 |
3.022e-02 | -3.50 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 20 |
PTGDS |
3.027e-02 | -3.50 | cholesterol homeostasis | biological process | GO:0042632 | 101 | 2 | 18204 | 49 |
RORA,APOE |
3.035e-02 | -3.49 | banded collagen fibril | cellular component | GO:0098643 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | fibrillar collagen trimer | cellular component | GO:0005583 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.039e-02 | -3.49 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 4 | 16828 | 49 |
SLC4A4,FGFR3,COL5A3,HIF3A |
3.040e-02 | -3.49 | USP30 (ubiquitin specific peptidase 30) | protein interactions | 84749 | 106 | 2 | 19454 | 50 |
QKI,FGFR3 |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | UGT1A9 (UDP glucuronosyltransferase family 1 member A9) | protein interactions | 54600 | 12 | 1 | 19454 | 50 |
PON2 |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.049e-02 | -3.49 | COLFI | pfam domains | PF01410 | 11 | 1 | 17795 | 50 |
COL5A3 |
3.049e-02 | -3.49 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 50 |
HIF3A |
3.058e-02 | -3.49 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 6 | 19454 | 50 |
NHSL1,DTNA,PTPRZ1,PARD3B,CTNNA2,APOE |
3.060e-02 | -3.49 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 42 |
CST3 |
3.063e-02 | -3.49 | spleen | COSMIC cancer mutations | spleen | 408 | 4 | 16828 | 49 |
NTM,PTPRZ1,PARD3B,TNIK |
3.073e-02 | -3.48 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 8 | 18094 | 47 |
NPAS3,SOX5,TRPS1,HIF3A,GLIS3,NFIA,RORA,ZBTB20 |
3.079e-02 | -3.48 | DNA-binding transcription repressor activity, RNA polymerase II-specific | molecular function | GO:0001227 | 263 | 3 | 18094 | 47 |
GLIS3,ZBTB20,TRPS1 |
3.082e-02 | -3.48 | sterol homeostasis | biological process | GO:0055092 | 102 | 2 | 18204 | 49 |
RORA,APOE |
3.092e-02 | -3.48 | POMK (protein O-mannose kinase) | protein interactions | 84197 | 266 | 3 | 19454 | 50 |
BMPR1B,CLU,PON2 |
3.111e-02 | -3.47 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 31 |
LSAMP,NTM |
3.139e-02 | -3.46 | calcium ion binding | molecular function | GO:0005509 | 683 | 5 | 18094 | 47 |
SPARCL1,NRXN1,PAMR1,RYR3,PCDH9 |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
RYR3,MSI2 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.147e-02 | -3.46 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 50 |
GPM6A,AHCYL2 |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
CLU,GPM6A |
3.151e-02 | -3.46 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 47 |
ATP1A2,RORA |
3.155e-02 | -3.46 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 14 | 18204 | 49 |
SOX5,PTGDS,NRXN1,CST3,APOE,ATP1A2,TRPS1,PTPRZ1,QKI,RORA,BMPR1B,ZBTB20,GLUL,CLU |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.168e-02 | -3.45 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 23 |
AHCYL2 |
3.168e-02 | -3.45 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 23 |
AHCYL2 |
3.179e-02 | -3.45 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 4 |
RORA |
3.184e-02 | -3.45 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 49 |
CST3 |
3.184e-02 | -3.45 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 49 |
CST3 |
3.184e-02 | -3.45 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | microglia differentiation | biological process | GO:0014004 | 12 | 1 | 18204 | 49 |
QKI |
3.184e-02 | -3.45 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 1 | 18204 | 49 |
APOE |
3.184e-02 | -3.45 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 49 |
SLC1A2 |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.193e-02 | -3.44 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.194e-02 | -3.44 | regulation of steroid metabolic process | biological process | GO:0019218 | 104 | 2 | 18204 | 49 |
APOE,RORA |
3.200e-02 | -3.44 | MIR34B (microRNA 34b) | protein interactions | 407041 | 109 | 2 | 19454 | 50 |
QKI,MSI2 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
CST3,DTNA,MSI2,FBXL7,SOX5,SPARCL1,PON2,COL5A3,TRPS1,HEPACAM,HIF3A,ATP13A4,FGFR3,NTM,NHSL1,CDH20,PITPNC1,AHCYL2,SLC4A4,CLU,ATP1A2,PAMR1,LSAMP,GPM6A,ZBTB20,GPC5,NFIA,RORA,TNIK,HPSE2,RYR3,QKI,NPAS3,SLC1A2,PTPRZ1,GLUL,BMPR1B,GLIS3,NRXN1,PTGDS,ZNRF3,PCDH9,MAML2,PREX2,SLC1A3,PARD3B,CPE,APOE |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
SLC1A3,PREX2,PARD3B,CPE,APOE,NRXN1,GLIS3,MAML2,PTGDS,ZNRF3,PCDH9,PTPRZ1,NPAS3,SLC1A2,GLUL,BMPR1B,ZBTB20,GPC5,GPM6A,NFIA,HPSE2,TNIK,RYR3,RORA,QKI,NHSL1,CDH20,PITPNC1,ATP1A2,CLU,SLC4A4,AHCYL2,LSAMP,PAMR1,HIF3A,HEPACAM,TRPS1,NTM,ATP13A4,FGFR3,PON2,COL5A3,MSI2,DTNA,CST3,FBXL7,SOX5,SPARCL1 |
3.213e-02 | -3.44 | ATXN1 (ataxin 1) | protein interactions | 6310 | 469 | 4 | 19454 | 50 |
NFIA,PTGDS,CST3,QKI |
3.229e-02 | -3.43 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 3 | 18094 | 47 |
SLC4A4,SLC1A2,SLC1A3 |
3.240e-02 | -3.43 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 3 | 18521 | 50 |
RYR3,DTNA,SPARCL1 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
3.254e-02 | -3.43 | SCARB1 (scavenger receptor class B member 1) | protein interactions | 949 | 110 | 2 | 19454 | 50 |
APOE,PON2 |
3.263e-02 | -3.42 | Protein digestion and absorption | KEGG pathways | hsa04974 | 89 | 2 | 7161 | 23 |
ATP1A2,COL5A3 |
3.263e-02 | -3.42 | Protein digestion and absorption | KEGG pathways | ko04974 | 89 | 2 | 7161 | 23 |
COL5A3,ATP1A2 |
3.284e-02 | -3.42 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 49 |
APOE |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.291e-02 | -3.41 | ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) | protein interactions | 8869 | 13 | 1 | 19454 | 50 |
PON2 |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
NRXN1 |
3.291e-02 | -3.41 | Rbm47 (RNA binding motif protein 47) | protein interactions | 245945 | 13 | 1 | 19454 | 50 |
QKI |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 50 |
APOE |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.309e-02 | -3.41 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 3 | 18204 | 49 |
PCDH9,CDH20,SPARCL1 |
3.321e-02 | -3.40 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 50 |
CPE |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.322e-02 | -3.40 | sulfur compound binding | molecular function | GO:1901681 | 271 | 3 | 18094 | 47 |
APOE,HPSE2,COL5A3 |
3.326e-02 | -3.40 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 47 |
SLC4A4 |
3.326e-02 | -3.40 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 47 |
ATP1A2 |
3.326e-02 | -3.40 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 47 |
BMPR1B |
3.332e-02 | -3.40 | tube development | biological process | GO:0035295 | 903 | 6 | 18204 | 49 |
HIF3A,APOE,RORA,QKI,NFIA,GLUL |
3.353e-02 | -3.40 | DNA-binding transcription repressor activity | molecular function | GO:0001217 | 272 | 3 | 18094 | 47 |
GLIS3,ZBTB20,TRPS1 |
3.387e-02 | -3.39 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 49 |
TRPS1,ZBTB20,NPAS3,COL5A3,ATP1A2,PARD3B,NTM,SLC4A4 |
3.388e-02 | -3.38 | regulation of developmental process | biological process | GO:0050793 | 2540 | 12 | 18204 | 49 |
SOX5,APOE,FGFR3,NRXN1,CST3,PTPRZ1,QKI,RORA,BMPR1B,TRPS1,TNIK,GLUL |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.395e-02 | -3.38 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 42 |
RYR3 |
3.405e-02 | -3.38 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 6 | 19454 | 50 |
NFIA,SLC1A3,ZBTB20,PON2,TRPS1,ATP13A4 |
3.418e-02 | -3.38 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 11 | 16828 | 49 |
NFIA,TRPS1,DTNA,SOX5,TNIK,FGFR3,PTPRZ1,PREX2,BMPR1B,ATP1A2,SLC4A4 |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
ZNRF3,DTNA |
3.438e-02 | -3.37 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 19 | 16828 | 49 |
ZNRF3,PCDH9,FGFR3,SOX5,RYR3,QKI,GLIS3,GPM6A,DTNA,TRPS1,HIF3A,GLUL,CLU,ATP1A2,NHSL1,PON2,PREX2,PTPRZ1,SLC1A3 |
3.438e-02 | -3.37 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 19 | 16828 | 49 |
TRPS1,HIF3A,DTNA,GLIS3,GPM6A,QKI,FGFR3,PCDH9,ZNRF3,RYR3,SOX5,PON2,NHSL1,SLC1A3,PREX2,PTPRZ1,GLUL,ATP1A2,CLU |
3.439e-02 | -3.37 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 49 |
GPC5,ZNRF3,APOE |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | 12 | 1 | 16828 | 49 |
QKI |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.444e-02 | -3.37 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 49 |
NFIA |
3.444e-02 | -3.37 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 49 |
NRXN1 |
3.444e-02 | -3.37 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 49 |
CTNNA2 |
3.444e-02 | -3.37 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 49 |
RORA |
3.464e-02 | -3.36 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 4 |
ATP1A2 |
3.464e-02 | -3.36 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 4 |
ATP1A2 |
3.466e-02 | -3.36 | small molecule biosynthetic process | biological process | GO:0044283 | 459 | 4 | 18204 | 49 |
PTGDS,SLC1A3,GLUL,QKI |
3.466e-02 | -3.36 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 38 |
SPARCL1 |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
ZBTB20,PCDH9 |
3.481e-02 | -3.36 | long-chain fatty acid metabolic process | biological process | GO:0001676 | 109 | 2 | 18204 | 49 |
QKI,PTGDS |
3.481e-02 | -3.36 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 49 |
APOE,NRXN1 |
3.481e-02 | -3.36 | positive regulation of tumor necrosis factor production | biological process | GO:0032760 | 109 | 2 | 18204 | 49 |
ZBTB20,CLU |
3.500e-02 | -3.35 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.530e-02 | -3.34 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 2 | 19454 | 50 |
BMPR1B,SOX5 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
CLU |
3.537e-02 | -3.34 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 49 |
CPE,NRXN1,TNIK,APOE |
3.540e-02 | -3.34 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 50 |
AHCYL2 |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.540e-02 | -3.34 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 50 |
APOE |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 50 |
NRXN1 |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.540e-02 | -3.34 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 50 |
MAML2 |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.559e-02 | -3.34 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 31 |
HIF3A |
3.559e-02 | -3.34 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.559e-02 | -3.34 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.570e-02 | -3.33 | blood microparticle | cellular component | GO:0072562 | 116 | 2 | 19108 | 49 |
CLU,APOE |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.581e-02 | -3.33 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 3 | 16828 | 49 |
PTPRZ1,FGFR3,GLIS3 |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
GLUL,SPARCL1 |
3.586e-02 | -3.33 | RBBP8 (RB binding protein 8, endonuclease) | protein interactions | 5932 | 116 | 2 | 19454 | 50 |
CTNNA2,CLU |
3.588e-02 | -3.33 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 8 | 18094 | 47 |
TRPS1,SOX5,NPAS3,NFIA,HIF3A,GLIS3,RORA,ZBTB20 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.593e-02 | -3.33 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 6 | 16828 | 49 |
PREX2,PCDH9,GLIS3,HIF3A,NFIA,PAMR1 |
3.613e-02 | -3.32 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 8 | 18094 | 47 |
ZBTB20,RORA,HIF3A,GLIS3,NFIA,NPAS3,TRPS1,SOX5 |
3.617e-02 | -3.32 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 49 |
TNIK,ZNRF3,FGFR3 |
3.631e-02 | -3.32 | tube morphogenesis | biological process | GO:0035239 | 685 | 5 | 18204 | 49 |
QKI,RORA,APOE,HIF3A,GLUL |
3.642e-02 | -3.31 | SYT6 (synaptotagmin 6) | protein interactions | 148281 | 117 | 2 | 19454 | 50 |
NRXN1,AHCYL2 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.647e-02 | -3.31 | HYOU1 (hypoxia up-regulated 1) | protein interactions | 10525 | 284 | 3 | 19454 | 50 |
CLU,CPE,FGFR3 |
3.657e-02 | -3.31 | regulation of gliogenesis | biological process | GO:0014013 | 112 | 2 | 18204 | 49 |
PTPRZ1,QKI |
3.678e-02 | -3.30 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 2 | 7161 | 23 |
ATP1A2,SLC4A4 |
3.678e-02 | -3.30 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 2 | 7161 | 23 |
SLC4A4,ATP1A2 |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.680e-02 | -3.30 | P4HA1 (prolyl 4-hydroxylase subunit alpha 1) | protein interactions | 5033 | 285 | 3 | 19454 | 50 |
APOE,DTNA,PON2 |
3.691e-02 | -3.30 | Visual phototransduction | REACTOME pathways | R-HSA-2187338 | 101 | 2 | 10285 | 31 |
APOE,GPC5 |
3.699e-02 | -3.30 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 50 |
TNIK,AHCYL2 |
3.704e-02 | -3.30 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 49 |
SLC1A2 |
3.704e-02 | -3.30 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
RYR3 |
3.706e-02 | -3.30 | Composition of Lipid Particles | WikiPathways | WP3601 | 10 | 1 | 5310 | 20 |
APOE |
3.710e-02 | -3.29 | calcium channel activity | molecular function | GO:0005262 | 117 | 2 | 18094 | 47 |
RYR3,GPM6A |
3.715e-02 | -3.29 | Neurexin-like | interpro domains | IPR003585 | 14 | 1 | 18521 | 50 |
NRXN1 |
3.717e-02 | -3.29 | dendrite development | biological process | GO:0016358 | 113 | 2 | 18204 | 49 |
CTNNA2,PREX2 |
3.717e-02 | -3.29 | positive regulation of tumor necrosis factor superfamily cytokine production | biological process | GO:1903557 | 113 | 2 | 18204 | 49 |
CLU,ZBTB20 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | 13 | 1 | 16828 | 49 |
QKI |
3.728e-02 | -3.29 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 42 |
PTGDS |
3.728e-02 | -3.29 | NC1_FIB | prosite domains | PS51461 | 11 | 1 | 12186 | 42 |
COL5A3 |
3.728e-02 | -3.29 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 42 |
TRPS1 |
3.749e-02 | -3.28 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 4 |
ATP1A2 |
3.750e-02 | -3.28 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 49 |
QKI,GPC5 |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.764e-02 | -3.28 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 20 |
SLC4A4 |
3.777e-02 | -3.28 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 2 | 18204 | 49 |
PTGDS,RORA |
3.779e-02 | -3.28 | NEDD4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 4734 | 494 | 4 | 19454 | 50 |
TNIK,FGFR3,GLIS3,MAML2 |
3.780e-02 | -3.28 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 49 |
APOE |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
TNIK |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.798e-02 | -3.27 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.814e-02 | -3.27 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 50 |
NFIA,AHCYL2 |
3.819e-02 | -3.27 | circulatory system development | biological process | GO:0072359 | 933 | 6 | 18204 | 49 |
CPE,GLUL,QKI,APOE,RORA,HIF3A |
3.828e-02 | -3.26 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 47 |
CPE |
3.828e-02 | -3.26 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 47 |
PITPNC1 |
3.837e-02 | -3.26 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 2 | 18204 | 49 |
PTGDS,QKI |
3.844e-02 | -3.26 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 38 |
RYR3 |
3.850e-02 | -3.26 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 31 |
MAML2 |
3.850e-02 | -3.26 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 31 |
MAML2 |
3.850e-02 | -3.26 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.872e-02 | -3.25 | MED15 (mediator complex subunit 15) | protein interactions | 51586 | 121 | 2 | 19454 | 50 |
NFIA,QKI |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
PARD3B,HIF3A |
3.904e-02 | -3.24 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 47 |
SLC1A2,SLC4A4,SLC1A3 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
PTPRZ1,SLC4A4,ATP13A4 |
3.919e-02 | -3.24 | homeostatic process | biological process | GO:0042592 | 1456 | 8 | 18204 | 49 |
ZBTB20,ATP13A4,RYR3,APOE,ATP1A2,SLC4A4,SLC1A3,RORA |
3.920e-02 | -3.24 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
NHSL1,DTNA |
3.930e-02 | -3.24 | MED31 (mediator complex subunit 31) | protein interactions | 51003 | 122 | 2 | 19454 | 50 |
CPE,QKI |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.947e-02 | -3.23 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 49 |
TRPS1,BMPR1B,FGFR3,TNIK,PREX2 |
3.954e-02 | -3.23 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 50 |
CDH20,PCDH9 |
3.964e-02 | -3.23 | system process | biological process | GO:0003008 | 2015 | 10 | 18204 | 49 |
CTNNA2,ATP1A2,SLC4A4,APOE,RYR3,NRXN1,PTPRZ1,SLC1A2,DTNA,SLC1A3 |
3.964e-02 | -3.23 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 49 |
SOX5 |
3.964e-02 | -3.23 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 49 |
NFIA |
3.964e-02 | -3.23 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 49 |
RORA |
3.964e-02 | -3.23 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 49 |
PTGDS |
3.964e-02 | -3.23 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 49 |
FGFR3 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
SLC1A2 |
3.964e-02 | -3.23 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 49 |
NFIA |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.977e-02 | -3.22 | KCNE3 (potassium voltage-gated channel subfamily E regulatory subunit 3) | protein interactions | 10008 | 294 | 3 | 19454 | 50 |
ZNRF3,TNIK,PCDH9 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.020e-02 | -3.21 | synapse assembly | biological process | GO:0007416 | 118 | 2 | 18204 | 49 |
NRXN1,GPM6A |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.035e-02 | -3.21 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 1 | 19454 | 50 |
CPE |
4.035e-02 | -3.21 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 50 |
APOE |
4.035e-02 | -3.21 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.054e-02 | -3.21 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 3 | 18204 | 49 |
CPE,TNIK,ZNRF3 |
4.065e-02 | -3.20 | membrane protein complex | cellular component | GO:0098796 | 1261 | 7 | 19108 | 49 |
ATP1A2,CDH20,BMPR1B,SLC1A3,RYR3,SLC1A2,CTNNA2 |
4.066e-02 | -3.20 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 49 |
PITPNC1,PREX2,CPE,PAMR1,ATP1A2,CLU,SLC4A4,NRXN1,NTM,MAML2,ZNRF3,ATP13A4,FGFR3,PTPRZ1,PON2,BMPR1B,GLUL,NFIA,ZBTB20,GPC5,SOX5,RYR3,HPSE2,TNIK,RORA |
4.066e-02 | -3.20 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 49 |
FGFR3,ZNRF3,ATP13A4,MAML2,NTM,NRXN1,PAMR1,CPE,SLC4A4,ATP1A2,CLU,PITPNC1,PREX2,RORA,HPSE2,TNIK,RYR3,SOX5,NFIA,GPC5,ZBTB20,BMPR1B,GLUL,PON2,PTPRZ1 |
4.078e-02 | -3.20 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 47 |
RORA |
4.078e-02 | -3.20 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 47 |
CLU |
4.079e-02 | -3.20 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 24 | 16828 | 49 |
COL5A3,PTPRZ1,PON2,SPARCL1,HPSE2,NFIA,ZBTB20,GPC5,GPM6A,DTNA,PARD3B,CLU,ATP1A2,SLC4A4,PREX2,SLC1A3,CDH20,ATP13A4,FGFR3,PCDH9,HIF3A,TRPS1,NRXN1,GLIS3 |
4.081e-02 | -3.20 | Circadian rythm related genes | WikiPathways | WP3594 | 207 | 3 | 5310 | 20 |
PTGDS,RORA,CST3 |
4.095e-02 | -3.20 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 24 | 16828 | 49 |
PON2,PTPRZ1,COL5A3,NFIA,DTNA,GPM6A,GPC5,ZBTB20,SPARCL1,HPSE2,CDH20,PREX2,SLC1A3,SLC4A4,CLU,ATP1A2,PARD3B,TRPS1,HIF3A,GLIS3,NRXN1,FGFR3,PCDH9,ATP13A4 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
LSAMP,NTM,HEPACAM,FGFR3 |
4.118e-02 | -3.19 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 10 | 16828 | 49 |
COL5A3,ATP13A4,PCDH9,HPSE2,RYR3,PITPNC1,FBXL7,CDH20,PREX2,PTPRZ1 |
4.126e-02 | -3.19 | cell junction assembly | biological process | GO:0034329 | 285 | 3 | 18204 | 49 |
NRXN1,GPM6A,CDH20 |
4.134e-02 | -3.19 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 50 |
TNIK |
4.134e-02 | -3.19 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 50 |
ATP1A2 |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
GPM6A,PITPNC1 |
4.166e-02 | -3.18 | RNF115 (ring finger protein 115) | protein interactions | 27246 | 126 | 2 | 19454 | 50 |
CST3,GLUL |
4.171e-02 | -3.18 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 7 | 16828 | 49 |
GPC5,CDH20,SLC1A2,SOX5,RYR3,ATP13A4,QKI |
4.196e-02 | -3.17 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 9 | 16828 | 49 |
PTPRZ1,PREX2,DTNA,CDH20,PARD3B,RORA,FGFR3,CPE,QKI |
4.196e-02 | -3.17 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 9 | 16828 | 49 |
PARD3B,FGFR3,RORA,QKI,CPE,PREX2,PTPRZ1,CDH20,DTNA |
4.221e-02 | -3.17 | COLFI | smart domains | SM00038 | 11 | 1 | 9717 | 38 |
COL5A3 |
4.223e-02 | -3.16 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 49 |
SOX5 |
4.223e-02 | -3.16 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
SLC1A3 |
4.223e-02 | -3.16 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 49 |
NRXN1 |
4.223e-02 | -3.16 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | glutamine family amino acid biosynthetic process | biological process | GO:0009084 | 16 | 1 | 18204 | 49 |
GLUL |
4.223e-02 | -3.16 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 49 |
AHCYL2 |
4.223e-02 | -3.16 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 49 |
SLC1A2 |
4.223e-02 | -3.16 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 49 |
ZNRF3 |
4.223e-02 | -3.16 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.242e-02 | -3.16 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 5 | 18204 | 49 |
GPM6A,SLC1A3,RYR3,SLC4A4,ATP1A2 |
4.270e-02 | -3.15 | lipoprotein metabolic process | biological process | GO:0042157 | 122 | 2 | 18204 | 49 |
GLUL,APOE |
4.273e-02 | -3.15 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 49 |
CLU |
4.282e-02 | -3.15 | hypothalamus | COSMIC cancer mutations | hypothalamus | 15 | 1 | 16828 | 49 |
QKI |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | Pef1 (penta-EF hand domain containing 1) | protein interactions | 67898 | 17 | 1 | 19454 | 50 |
QKI |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 50 |
APOE |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 50 |
MAML2 |
4.286e-02 | -3.15 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 50 |
AHCYL2,NRXN1 |
4.286e-02 | -3.15 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 50 |
TRPS1,ZBTB20 |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.321e-02 | -3.14 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 3 | 19454 | 50 |
QKI,RORA,DTNA |
4.327e-02 | -3.14 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 47 |
PTPRZ1 |
4.327e-02 | -3.14 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 47 |
PTPRZ1 |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
FGFR3,CPE |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
SOX5,ZBTB20 |
4.350e-02 | -3.13 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 4 | 18204 | 49 |
ATP1A2,APOE,SLC1A3,NRXN1 |
4.350e-02 | -3.13 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 49 |
BMPR1B,NFIA,FGFR3,SOX5 |
4.362e-02 | -3.13 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 6 | 16828 | 49 |
ATP1A2,FGFR3,PTGDS,SPARCL1,PTPRZ1,NPAS3 |
4.377e-02 | -3.13 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 4 | 18204 | 49 |
NRXN1,SLC1A3,APOE,ATP1A2 |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 42 |
CPE |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 42 |
CPE |
4.397e-02 | -3.12 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 49 |
ZBTB20,APOE |
4.407e-02 | -3.12 | RSPH1 (radial spoke head component 1) | protein interactions | 89765 | 130 | 2 | 19454 | 50 |
GLUL,CLU |
4.410e-02 | -3.12 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 8 | 18094 | 47 |
TRPS1,SOX5,NPAS3,NFIA,GLIS3,HIF3A,RORA,ZBTB20 |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
LSAMP,NTM,HEPACAM,PTPRZ1,FGFR3 |
4.430e-02 | -3.12 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 31 |
PTGDS |
4.432e-02 | -3.12 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 20 |
RYR3 |
4.432e-02 | -3.12 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 20 |
BMPR1B |
4.437e-02 | -3.12 | brain development | biological process | GO:0007420 | 724 | 5 | 18204 | 49 |
CTNNA2,ATP1A2,SLC1A2,RORA,PCDH9 |
4.467e-02 | -3.11 | regulation of cellular process | biological process | GO:0050794 | 11468 | 37 | 18204 | 49 |
SLC1A2,RORA,TNIK,MAML2,DTNA,MSI2,CLU,SPARCL1,GLUL,GPC5,PTGDS,SOX5,PITPNC1,NFIA,APOE,SLC4A4,FGFR3,NPAS3,RYR3,PTPRZ1,QKI,GLIS3,HPSE2,BMPR1B,ZNRF3,GPM6A,TRPS1,CPE,PREX2,ZBTB20,SLC1A3,ATP1A2,CTNNA2,HIF3A,NRXN1,HEPACAM,CST3 |
4.468e-02 | -3.11 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.468e-02 | -3.11 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
RORA,NFIA |
4.472e-02 | -3.11 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 8 | 16828 | 49 |
ATP13A4,FGFR3,PCDH9,PARD3B,HPSE2,ATP1A2,RYR3,CPE |
4.477e-02 | -3.11 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 44 |
NPAS3,HIF3A |
4.481e-02 | -3.11 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 49 |
CTNNA2 |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
SLC1A2 |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
RYR3 |
4.481e-02 | -3.11 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 49 |
CLU |
4.481e-02 | -3.11 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 49 |
TNIK |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
NRXN1,GLIS3,MAML2,PTGDS,ZNRF3,PCDH9,PREX2,SLC1A3,PARD3B,CPE,APOE,ZBTB20,GPC5,GPM6A,NFIA,TNIK,RYR3,HPSE2,RORA,QKI,PTPRZ1,NPAS3,SLC1A2,NKAIN3,GLUL,BMPR1B,HIF3A,HEPACAM,TRPS1,NTM,ATP13A4,FGFR3,NHSL1,CDH20,PITPNC1,ATP1A2,CLU,SLC4A4,AHCYL2,LSAMP,PAMR1,MSI2,DTNA,CST3,FBXL7,SOX5,SPARCL1,PON2,COL5A3 |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 50 |
APOE |
4.529e-02 | -3.09 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 50 |
PTGDS |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
FGFR3 |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.531e-02 | -3.09 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 3 | 18204 | 49 |
NRXN1,QKI,PTPRZ1 |
4.535e-02 | -3.09 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 3 | 19454 | 50 |
AHCYL2,TNIK,DTNA |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.569e-02 | -3.09 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 49 |
ATP1A2,RYR3,DTNA |
4.569e-02 | -3.09 | carboxylic acid transport | biological process | GO:0046942 | 297 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,APOE |
4.576e-02 | -3.08 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 47 |
PITPNC1 |
4.576e-02 | -3.08 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 47 |
RYR3 |
4.596e-02 | -3.08 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 38 |
NFIA |
4.596e-02 | -3.08 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 38 |
TRPS1 |
4.606e-02 | -3.08 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 6 | 16828 | 49 |
SPARCL1,ATP1A2,PTGDS,FGFR3,PTPRZ1,NPAS3 |
4.607e-02 | -3.08 | organic acid transport | biological process | GO:0015849 | 298 | 3 | 18204 | 49 |
SLC1A3,APOE,SLC1A2 |
4.613e-02 | -3.08 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 50 |
PARD3B,PREX2 |
4.629e-02 | -3.07 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | Pathway Interaction DB | hif1apathway | 15 | 1 | 2226 | 7 |
HIF3A |
4.655e-02 | -3.07 | myelination | biological process | GO:0042552 | 128 | 2 | 18204 | 49 |
CLU,QKI |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 50 |
CST3 |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.674e-02 | -3.06 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 5 | 19454 | 50 |
CLU,PON2,MSI2,SLC1A2,FGFR3 |
4.676e-02 | -3.06 | protein-folding chaperone binding | molecular function | GO:0051087 | 133 | 2 | 18094 | 47 |
CLU,ATP1A2 |
4.696e-02 | -3.06 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 44 |
CDH20,PCDH9 |
4.716e-02 | -3.05 | BMP4 (bone morphogenetic protein 4) | protein interactions | 652 | 135 | 2 | 19454 | 50 |
BMPR1B,CLU |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
ATP13A4,FGFR3,NTM,HEPACAM,TRPS1,HIF3A,PAMR1,LSAMP,SLC4A4,AHCYL2,CLU,ATP1A2,PITPNC1,NHSL1,CDH20,SPARCL1,SOX5,FBXL7,CST3,DTNA,MSI2,COL5A3,PON2,PTGDS,ZNRF3,PCDH9,MAML2,GLIS3,NRXN1,CPE,APOE,PARD3B,SLC1A3,PREX2,QKI,RORA,HPSE2,RYR3,TNIK,NFIA,GPM6A,ZBTB20,GPC5,BMPR1B,GLUL,NKAIN3,NPAS3,SLC1A2,PTPRZ1 |
4.738e-02 | -3.05 | dicarboxylic acid catabolic process | biological process | GO:0043649 | 18 | 1 | 18204 | 49 |
GLUL |
4.738e-02 | -3.05 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 49 |
ATP1A2 |
4.738e-02 | -3.05 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 49 |
CST3 |
4.738e-02 | -3.05 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 49 |
RORA |
4.738e-02 | -3.05 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 49 |
ZNRF3 |
4.738e-02 | -3.05 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 49 |
APOE |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.774e-02 | -3.04 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.786e-02 | -3.04 | axon ensheathment | biological process | GO:0008366 | 130 | 2 | 18204 | 49 |
CLU,QKI |
4.786e-02 | -3.04 | ensheathment of neurons | biological process | GO:0007272 | 130 | 2 | 18204 | 49 |
QKI,CLU |
4.793e-02 | -3.04 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 20 |
RYR3 |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
PREX2,ATP1A2,TNIK |
4.824e-02 | -3.03 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 47 |
BMPR1B |
4.824e-02 | -3.03 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 47 |
ATP1A2 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | optic_nerve | COSMIC cancer mutations | optic_nerve | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.852e-02 | -3.03 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.866e-02 | -3.02 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 2 | 18094 | 47 |
GPM6A,RYR3 |
4.918e-02 | -3.01 | amino acid transport | biological process | GO:0006865 | 132 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.946e-02 | -3.01 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 3 | 14470 | 44 |
RYR3,DTNA,SPARCL1 |
4.962e-02 | -3.00 | thalamus | COSMIC cancer mutations | thalamus | 284 | 3 | 16828 | 49 |
FGFR3,DTNA,QKI |
4.968e-02 | -3.00 | DUSP22 (dual specificity phosphatase 22) | protein interactions | 56940 | 139 | 2 | 19454 | 50 |
QKI,CTNNA2 |
4.968e-02 | -3.00 | NEFM (neurofilament medium chain) | protein interactions | 4741 | 139 | 2 | 19454 | 50 |
APOE,TNIK |
4.985e-02 | -3.00 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 2 | 18204 | 49 |
ATP1A2,RYR3 |
4.995e-02 | -3.00 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 1 | 18204 | 49 |
NRXN1 |
4.995e-02 | -3.00 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 49 |
NRXN1 |
4.995e-02 | -3.00 | cerebellar Purkinje cell layer morphogenesis | biological process | GO:0021692 | 19 | 1 | 18204 | 49 |
RORA |
4.995e-02 | -3.00 | vascular associated smooth muscle cell differentiation | biological process | GO:0035886 | 19 | 1 | 18204 | 49 |
QKI |
4.995e-02 | -3.00 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 49 |
APOE |
4.995e-02 | -3.00 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 49 |
TNIK |
4.995e-02 | -3.00 | regulation of circadian sleep/wake cycle | biological process | GO:0042749 | 19 | 1 | 18204 | 49 |
PTGDS |
4.995e-02 | -3.00 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 1 | 18204 | 49 |
ATP1A2 |